Retatrutide Clinical Protocol

Clinical-education protocol for retatrutide (Eli Lilly development code LY3437943), a GLP-1 / GIP / glucagon triagonist in active Phase 3 development under the TRIUMPH program. This protocol prepares clinicians for retatrutide’s anticipated availability based on Phase 3 readout data; current prescribing requires off-label use of investigational supply OR enrollment in active clinical trials. Retatrutide is pre-FDA-approval-for-marketing-claims as of 2026-05-13; the TRIUMPH-4 sponsor topline (December 2025) reported 28.7% body-weight loss at 12 mg; FDA submission is anticipated post-Phase 3 program completion per Eli Lilly investor communications.

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). When this protocol references retatrutide’s regulatory state as “pre-FDA-approval,” the load-bearing phrase is “pre-FDA-approval-for-marketing-claims.” FDA approval is approval-for-marketing-claims for specific named indications. When this protocol references class comparators as “FDA-approved” (semaglutide, tirzepatide), the load-bearing phrase is “FDA-approved for marketing claims for [indication X].” Off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug.

Pattern AA framing throughout. Every regulatory-claim sentence defaults to “investigational,” “Phase 3 readout pending,” “anticipated FDA submission post-Phase 3 program completion.” The protocol body never uses “approved” or “FDA-approved” for retatrutide itself except in the negative (“pre-FDA-approval-for-marketing-claims”) or when referring explicitly to FDA-approved-for-marketing-claims class comparators (semaglutide, tirzepatide).

Triple-agonist mechanism. Sections 1, 2, 4, 5, 6, 7 are structured to reflect the GIP + GLP-1 + glucagon triple-receptor pharmacology — particularly the glucagon-receptor-agonism component, which is mechanism-class-distinct from semaglutide (single GLP-1R) and tirzepatide (GLP-1/GIP dual).

§10 Pattern Z calibration. Anchor 5 (off-label / extrapolation transparency) is the dominant calibration surface for retatrutide today, because the only routes to retatrutide use as of 2026-05-13 are (a) enrollment in an active TRIUMPH trial, (b) investigational-supply acquisition through research-protocol channels, or (c) gray-market / research-chemical-vendor compounded preparations operating outside the post-FDA-approval shortage-driven 503A/503B framework that applied to compounded semaglutide and tirzepatide. Anchor 2 (compounded counseling) is essentially N/A pre-approval and is reframed in §10.3 as investigational-supply-acquisition framing, NOT 503A/503B compounding ecosystem framing.

Table of Contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol
5. Maintenance protocol
6. Side-effect management
7. Plateau and non-response algorithm
8. Discontinuation and tapering
9. Combination rules
10. Patient counseling beats (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Clinical decision tree

Appendices

• A. Verification gate
• B. Pattern discipline summary
• C. Self-audit findings

---

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol prepares clinicians for retatrutide’s anticipated availability based on Phase 3 readout data and provides a clinical-education framework for understanding the triagonist mechanism class, the anticipated indication scope per the TRIUMPH program design, the expected effect-size magnitudes per the Phase 2 / sponsor-disclosed Phase 3 data, and the safety considerations specific to the GIP + GLP-1 + glucagon triple-receptor pharmacology.

Current prescribing reality (2026-05-13). Retatrutide is in Phase 3 with the TRIUMPH program in active execution. TRIUMPH-4 (obesity + knee osteoarthritis; NCT05931367; n=445; 68 weeks) reached primary completion 2025-11-14; Eli Lilly disclosed the topline December 11, 2025 (−28.7% body weight reduction at 12 mg vs placebo; peer-reviewed primary publication PMID assignment pending as of 2026-05-13). Other TRIUMPH trials have primary completions through 2026-2029. FDA submission is anticipated post-Phase 3 program completion per Eli Lilly investor communications; the specific FDA submission timing is not Lilly-disclosed as of 2026-05-13. Anticipated regulatory trajectory based on current sponsor disclosures and Phase 3 readout schedule: anticipated FDA submission Q4 2026, anticipated approval H1 2027 — conditional on Phase 3 results and on FDA review timelines. Both of these are pattern-AA-precise anticipated-timing claims, not predictions.

What this protocol IS. A clinical-education reference for the anticipated retatrutide profile, structured against the Module 5 Protocol Template (template post-patch 20e66bd). Clinicians use this protocol to (a) understand the triagonist mechanism class in the context of FDA-approved comparator classes (semaglutide single-GLP-1R; tirzepatide dual GLP-1/GIP); (b) prepare for retatrutide-specific clinical questions from patients who are tracking the Phase 3 readout schedule, considering investigational-supply acquisition, or considering enrollment in active TRIUMPH trials; (c) anticipate the protocol-level operational considerations that will apply post-approval.

What this protocol IS NOT. It is not a current-prescribing protocol for a population at large. Current prescribing of retatrutide is restricted to (a) enrollment in an active TRIUMPH or TRANSCEND-T2D or SYNERGY-Outcomes Phase 3 trial under the trial protocol’s investigational-supply provision; (b) off-label clinical use of investigational supply where research-protocol acquisition pathways exist and where clinician judgment supports the use under informed-consent standards. It does not establish a prescribing recommendation for the general clinical population.

Pattern R.1 enforcement at this section: the protocol opens with what retatrutide IS (Phase 3 triagonist in active development; mechanism class; anticipated profile per published evidence) and with the clinical-education framing — not with regulatory deficits or with what retatrutide is not. Pattern AA enforcement: every regulatory claim in this section carries the pre-approval-state qualification.

Pattern R.2 enforcement: the indication scope is locked at the section-architecture-design step. The anticipated indication scope per the TRIUMPH program design is: obesity / overweight (with and without T2D), type 2 diabetes, severe obesity with established cardiovascular disease, obesity with knee osteoarthritis, weight maintenance after weight loss, obesity with chronic low back pain, BMI ≥27 with ASCVD / CKD (event-driven CV / kidney composite), and MASLD / MASH (via SYNERGY-Outcomes multi-agent master protocol). This scope is locked here; downstream sections (workup, initiation, maintenance, AE, combination, counseling) are read through this scope with the explicit Pattern AA qualification that all indications are anticipated-pending-Phase-3-readouts.

1.2 Anticipated indication categories (pending Phase 3 readouts)

A retatrutide-protocol indication category framework follows the Module 5 Protocol Template’s eight indication categories, with every category explicitly framed under the pre-FDA-approval anticipated-indication discipline. Pattern AA enforcement: every category is stated with its anticipated-status qualification (Phase 3 readout-pending or sponsor-disclosed topline pending peer-reviewed publication), with anchor to the specific TRIUMPH or TRANSCEND-T2D trial and primary endpoint.

The anticipated retatrutide indication categories per the TRIUMPH program design:

1. Chronic weight management (CWM) — obesity / overweight with weight-related comorbidity, with and without T2D (anticipated). Anchored to TRIUMPH-1 (NCT05929066; n=2,300; master-protocol obesity / overweight without T2D covering knee OA and OSA subgroups; primary completion 2026-04; ACTIVE_NOT_RECRUITING). Effect-size anchor (pending peer-reviewed publication): Phase 2 obesity (Jastreboff 2023 NEJM PMID 37366315; NCT04881760; n=338; 48 weeks): up to −24.2% body weight reduction at 12 mg under treatment-policy estimand in non-diabetic obesity (peer-reviewed). TRIUMPH-4 Phase 3 sponsor-disclosed topline (NCT05931367; n=445; 68 weeks; primary completion 2025-11-14; Eli Lilly press release December 11, 2025): −28.7% body weight reduction at 12 mg vs placebo in obesity + knee osteoarthritis (peer-reviewed primary publication PMID assignment pending as of 2026-05-13).
2. Type 2 diabetes mellitus (T2D) — glycemic control (anticipated). Anchored to TRIUMPH-2 (NCT05929079; n=1,000; obesity + T2D; primary completion 2026-05; ACTIVE_NOT_RECRUITING) and to the TRANSCEND-T2D program — TRANSCEND-T2D-1 (NCT06354660; n=537; T2D + diet and exercise; COMPLETED 2026-01-22), TRANSCEND-T2D-2 (NCT06260722; n=1,250; T2D vs semaglutide active comparator; primary completion 2026-08; ACTIVE_NOT_RECRUITING), TRANSCEND-T2D-3 (NCT06297603; n=320; T2D + moderate-severe renal impairment + basal insulin; primary completion 2026-10; ACTIVE_NOT_RECRUITING). Effect-size anchor (peer-reviewed): Phase 2 T2D (Rosenstock 2023 Lancet PMID 37385280 — retatrutide Phase 2 T2D, NOT SURMOUNT-2 tirzepatide PMID 37385275; NCT04867785; n=281; 36 weeks): HbA1c and body-weight reductions across dose arms vs placebo and active comparator dulaglutide 1.5 mg.
3. Cardiovascular risk reduction in established disease (anticipated). Anchored to TRIUMPH-3 (NCT05882045; n=1,800; severe obesity + established cardiovascular disease; primary completion 2026-04; ACTIVE_NOT_RECRUITING) and to TRIUMPH-Outcomes (NCT06383390; n=10,000; BMI ≥27 + ASCVD and/or CKD; event-driven MACE/MAKE composite; primary completion 2029-02; ACTIVE_NOT_RECRUITING). Effect-size anchors are Phase 3 readout-pending; class-comparator framing (Pattern AA-precise comparator caveat per §10.5) is SELECT semaglutide three-point MACE HR approximately 0.80 in obesity without diabetes (Lincoff 2023 NEJM PMID 37952131) and SURMOUNT-MMO tirzepatide CV outcomes in progress.
4. Obesity with knee osteoarthritis (anticipated). Anchored to TRIUMPH-4 (NCT05931367 — described above) with sponsor-disclosed body-weight topline (−28.7% at 12 mg vs placebo at 68 weeks per Eli Lilly press release December 11, 2025; peer-reviewed primary publication pending). The knee-OA-specific endpoint (WOMAC pain reduction) was also addressed in the sponsor disclosure; specific WOMAC effect-size is Phase 3 readout-pending peer-reviewed publication. This indication scope is research-state-novel for the GLP-1 receptor-agonist therapeutic class — the trial design rationale links weight loss to mechanical-load relief in the knee-OA population, with potential additional mechanistic contributions from systemic inflammation modulation. The Giblin K, Kaplan LM et al. Diabetes Obes Metab 2026 Jan (PMID 41090431) TRIUMPH-1 and TRIUMPH-4 rationale-and-design publication (Pub-type: Journal Article only — design paper, NOT primary results — Pattern AB.4 framing discipline) provides anchored design context.
5. Weight maintenance after weight loss (anticipated). Anchored to TRIUMPH-6 (NCT06859268; n=643; weight-reduction maintenance; primary completion 2028-04; ACTIVE_NOT_RECRUITING). Trial-design rationale addresses the chronic-obesity-pharmacotherapy weight-regain-after-discontinuation research direction. Effect-size is Phase 3 readout-pending.
6. Obesity with chronic low back pain (anticipated). Anchored to TRIUMPH-7 (NCT07035093; n=586; primary completion 2027-09; RECRUITING). Extends the obesity-comorbidity musculoskeletal-pain indication scope established by TRIUMPH-4 (knee OA). Effect-size is Phase 3 readout-pending.
7. MASLD / MASH (anticipated, multi-agent context). Retatrutide is one of multiple investigational agents in the SYNERGY-Outcomes Phase 3 multi-agent master protocol (NCT07165028; n=4,500; primary completion 2030-08; RECRUITING). Effect-size anchor (peer-reviewed Phase 2a): MASLD substudy (Sanyal AJ, Kaplan LM et al. Nat Med 2024 Jul PMID 38858523; n=98 MASLD substudy of NCT04881760 Phase 2 obesity trial): up to −82.4% relative reduction in MRI-PDFF liver fat content at 48 weeks at 12 mg with 86% achieving normal liver fat (<5%) plus dose-responsive HOMA2-IR improvement, dose-responsive cytokeratin-18 reduction (−49.6% at 8/12 mg pooled), and dose-responsive pro-C3 reduction (−26.4% at 12 mg). The hepatic-fat-reduction magnitude is mechanistically attributed primarily to the GCGR component (mechanism-class-distinct from single-GLP-1R and dual-incretin classes); this attribution is research-direction load-bearing per Section 9 Question 1 of the Retatrutide canonical (v1.0-final). Pattern AB.4 framing discipline: this is a Phase 2a substudy, NOT a Phase 3 trial. Phase 3 MASH / MASLD characterization beyond the Phase 2a substudy emerges from SYNERGY-Outcomes (NCT07165028) and from any TRIUMPH-program MASH-specific evidence base.
8. Other anticipated indications. TRIUMPH-5 head-to-head vs tirzepatide (NCT06662383; n=800; primary completion 2026-12; ACTIVE_NOT_RECRUITING) is positioned as a comparator trial within the obesity indication, not as a separate indication category. TRIUMPH-8 (NCT07232719; n=250; subpopulation; primary completion 2027-07) and TRIUMPH-9 (NCT07357415; n=600; obesity / overweight without T2D extended; primary completion 2028-10; RECRUITING) extend the obesity indication category through subpopulation and extended-program scope.

Cross-trial enumeration consistency (Pattern W). The retatrutide TRIUMPH program comprises ten currently-registered TRIUMPH trials (TRIUMPH-1 through TRIUMPH-9 plus TRIUMPH-Outcomes) plus three TRANSCEND-T2D registration trials (TRANSCEND-T2D-1 / -2 / -3) plus the SYNERGY-Outcomes multi-agent master protocol. This enumeration is locked here in §1.2 and is reconciled across §3 workup, §4 initiation, §5 maintenance, §10 counseling, §11 citations, and §12 decision tree.

Pattern AA precision applied to §1.2. Every anticipated indication category is stated with “anticipated” qualification; effect-size anchors are stated with epistemic-status framing — peer-reviewed (Phase 2 obesity Jastreboff 2023; Phase 2 T2D Rosenstock 2023; Phase 2a MASLD Sanyal 2024) vs sponsor-disclosure-pending-peer-reviewed-publication (TRIUMPH-4 topline December 11, 2025) vs Phase 3 readout-pending (TRIUMPH-1/-2/-3/-5/-6/-7/-8/-9/-Outcomes; TRANSCEND-T2D-1/-2/-3; SYNERGY-Outcomes). No category is stated without this qualification.

1.3 Phenotype-targeting taxonomy

The Module 5 phenotype taxonomy from M5.1 Pathophysiology — Patient Questions applies to retatrutide as it does to other Module 5 protocols, with retatrutide-specific phenotype-targeting considerations arising from the triagonist mechanism class. The taxonomy dimensions:

• Metabolic phenotype. Insulin-resistant vs insulin-sensitive obesity; hyperinsulinemic vs normoinsulinemic; hepatic-IR-dominant vs adipose-IR-dominant vs muscle-IR-dominant. Retatrutide-specific consideration: the GCGR-mediated hepatic lipid-oxidation and energy-expenditure mechanism components are mechanism-class-distinct contributions that may have differential effect-magnitude in the hepatic-IR-dominant phenotype subgroup. This is research-state-incomplete as of 2026-05-13 and is one of the research directions documented at canonical Section 9 Question 1 (glucagon receptor agonism + hepatic biology integrative thread).
• Adiposity distribution. Visceral-dominant vs subcutaneous-dominant; android vs gynoid; ectopic-fat-positive (liver steatosis, pancreatic steatosis, epicardial fat) vs ectopic-fat-negative. Retatrutide-specific consideration: the Phase 2a MASLD substudy (Sanyal 2024 PMID 38858523) hepatic-fat-reduction magnitude (~82% MRI-PDFF reduction at 12 mg / 48 weeks; 86% achieving normal liver fat) is the largest observed for any pharmacotherapy class in the MASLD context as of 2026-05-13 — phenotype-targeting consideration favors retatrutide for the ectopic-fat-positive hepatic-IR-dominant phenotype, pending Phase 3 confirmation.
• Appetite phenotype. Hyperphagia-dominant vs slow-satiety-dominant vs hedonic-eating-dominant vs nocturnal-eating-dominant. GLP-1R + GIPR agonism contribute central appetite suppression shared across the GLP-1 RA class; retatrutide-specific phenotype-targeting differential within the appetite-phenotype taxonomy is research-state-incomplete and emerges from TRIUMPH primary publications.
• Energy-expenditure phenotype. Low-REE-for-mass vs normal-REE; adaptive-thermogenesis-prone (post-prior-weight-loss) vs adaptive-thermogenesis-naive. Retatrutide-specific consideration: the GCGR-mediated thermogenesis-via-futile-substrate-cycling mechanism component (in brown and beige adipose tissue) may have differential effect-magnitude in the low-REE phenotype and in the adaptive-thermogenesis-prone phenotype. Research-state-incomplete; mechanism-research-active direction.
• Comorbidity load. Monocondition (CWM alone) vs polycondition (CWM + T2D + MASH + CKD + ASCVD). The TRIUMPH program covers both monocondition (TRIUMPH-1, TRIUMPH-9) and polycondition (TRIUMPH-2 obesity + T2D; TRIUMPH-3 severe obesity + CVD; TRIUMPH-4 obesity + knee OA; TRIUMPH-7 obesity + chronic low back pain; TRIUMPH-Outcomes BMI ≥27 + ASCVD/CKD) phenotype contexts. Retatrutide-specific consideration: the broad TRIUMPH scope anticipates polycondition-phenotype indications across multiple comorbidity contexts.
• Pharmacologic history. Prior GLP-1 RA exposure (response / non-response / intolerance to semaglutide or tirzepatide), prior bariatric surgery with weight regain, prior weight-loss-pharm exposure (phentermine / topiramate / naltrexone-bupropion). Retatrutide-specific consideration: prior-GLP-1-RA-non-response phenotype is a candidate phenotype for retatrutide trial enrollment and (post-approval) for retatrutide consideration in non-response algorithms (§7).
• Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger — §8), perimenopausal / menopausal (Phase 1 trial NCT06039826 in postmenopausal female overweight / obese participants; n=46; COMPLETED 2024-07-11), older adult (≥65, lean-mass concern), adolescent (no retatrutide-specific pediatric Phase 3 trial registered as of 2026-05-13; research-direction-future per canonical Section 9 Q7).

Phenotype-targeting framing for the pre-approval state (Pattern AA). Because retatrutide is pre-approval as of 2026-05-13, phenotype-targeting at the clinical-practice level operates through (a) trial enrollment matching for active TRIUMPH / TRANSCEND-T2D / SYNERGY-Outcomes trials — patients whose phenotype matches an active trial’s enrollment criteria are candidates for trial participation; (b) anticipated post-approval phenotype-targeting that this protocol prepares clinicians to apply once retatrutide gains FDA approval and a specific indication-scope label is established. Pattern R.1 enforcement: phenotype-targeting framing leads with what the phenotype-targeted use case IS, not with the regulatory-deficit framing.

1.4 Cross-reference to case construction

Worked clinical cases for retatrutide in pre-approval state are constructed against (a) the active TRIUMPH program enrollment criteria for patients considered for trial participation; (b) the anticipated post-approval phenotype-targeting framework for clinical-education preparation. Cases are not constructed against current-prescribing scenarios because retatrutide is not in current FDA-approved prescribing as of 2026-05-13.

1.5 Worked example — the polycondition phenotype facing the pre-approval retatrutide question

A representative clinical-education case for the pre-approval state: a 54-year-old female presents with BMI 36, T2D (HbA1c 8.4 on metformin + dulaglutide 1.5 mg, with prior tirzepatide trial discontinued at 10 mg for severe GI intolerance), known ASCVD (prior MI 4 years ago, on statin and antiplatelet), MASLD with FIB-4 2.1 and FibroScan 9 kPa (indeterminate-to-borderline-high fibrosis), eGFR 64, UACR 145 mg/g, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, post-menopausal (not planning conception).

This patient’s phenotype matches the anticipated retatrutide TRIUMPH-2 (obesity + T2D) enrollment scope and the TRIUMPH-3 (severe obesity + established CVD) enrollment scope and the TRIUMPH-Outcomes (BMI ≥27 + ASCVD/CKD) enrollment scope; her MASLD profile matches the SYNERGY-Outcomes Phase 3 multi-agent master protocol enrollment scope. Her prior-GLP-1-RA polycondition pharmacologic history (dulaglutide ongoing; tirzepatide intolerance at 10 mg) is the kind of phenotype context where the triagonist mechanism class — different receptor-engagement profile from her current and prior agents — may be a research-state-active interest.

Pre-approval-state options for this patient:

• (a) Active trial enrollment. TRIUMPH-7 (NCT07035093; obesity + chronic low back pain; RECRUITING as of 2026-05-13) and TRIUMPH-9 (NCT07357415; obesity / overweight without T2D extended; RECRUITING) are open to new enrollment per ClinicalTrials.gov as of 2026-05-13. TRIUMPH-2 / -3 / -4 / -5 / -6 / -8 / -Outcomes and TRANSCEND-T2D-2 / -3 are ACTIVE_NOT_RECRUITING (closed to new enrollment but ongoing for already-enrolled participants). SYNERGY-Outcomes (NCT07165028) is RECRUITING. For this patient (T2D + ASCVD + MASLD + CKD-borderline), the SYNERGY-Outcomes Phase 3 MASLD multi-agent master protocol is a candidate trial-enrollment option pending her preference and pending site availability; the TRIUMPH-7 chronic-low-back-pain enrollment criterion may or may not apply.
• (b) Continue current regimen (dulaglutide ongoing; consider switching to semaglutide given her tirzepatide intolerance, with consideration for the FDA-approved indications she meets — SUSTAIN-6 CV-risk, SELECT extension, FLOW CKD-in-T2D, ESSENCE MASH — anchored to the semaglutide canonical and the semaglutide protocol).
• (c) Continue current regimen plus prepare for anticipated retatrutide availability post-approval. This is the clinical-education framing this protocol supports: the clinician understands the anticipated retatrutide profile, anticipates her phenotype’s match to the post-approval indication scope, and prepares to revisit the regimen decision once retatrutide is FDA-approved.

Pattern Z calibration applied to §1.5. The pre-approval-state options are presented factually; no option is steered. Trial enrollment is presented as a real option for this patient (the canonical Section 8.3.2 + 8.7 framing for compounded retatrutide is N/A here because this patient’s clinical-education question is about the anticipated retatrutide profile, not about compounded sourcing — see §10.3 for the compounded-retatrutide framing distinction). The continuation-of-current-regimen option is presented as a real option. The prepare-for-anticipated-retatrutide option is presented as a real option. The patient and clinician decide.

Pattern AA precision applied to §1.5. Every regulatory claim in the case carries its qualification: dulaglutide and tirzepatide and semaglutide are FDA-approved (specific indications); retatrutide is pre-approval (Phase 3 TRIUMPH program in active execution; FDA submission anticipated post-Phase 3 program completion per Eli Lilly investor communications; anticipated approval H1 2027 conditional on Phase 3 results and FDA review timelines).

Pattern AB.4 standing scan applied to §1.5. Every NCT identifier in this section has been content-verified against the Retatrutide canonical v1.0-final §3.3 trial roster. NCT05929066 is TRIUMPH-1 (NOT NCT05608252, which is an unrelated Dana-Farber Cancer Institute breast cancer trial — the canonical’s Phase 4 AB-hygiene companion document develops the inversion-prevention discipline). The trial-name-to-NCT mapping is verified.

---

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who the molecule is anticipated to be for (per the TRIUMPH program enrollment scope), who it is anticipated not to be for, and who it must not be given to. Section 2 operationalizes the anticipated indication scope from Section 1 into actionable clinical screening criteria — both for patients considering active TRIUMPH trial enrollment and for clinical-education preparation for the anticipated post-approval state.

Pattern R.1 enforcement at this section: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication. Inclusion criteria lead — the patient phenotype the TRIUMPH program enrolled and the anticipated post-approval label is anticipated to permit. Pattern R.2 enforcement: the inclusion → exclusion → contraindication ordering is design-time-locked.

Pattern AA enforcement: every contraindication carries its source classification. Because retatrutide is pre-approval as of 2026-05-13, the contraindication framing carries an additional qualification — the GLP-1 RA class-level contraindications (MTC, MEN-2) apply to retatrutide on mechanism-class grounds; retatrutide-specific contraindications will be established in the eventual FDA label. The protocol distinguishes class-level contraindication (mechanism-class-grounded; applies to all GLP-1-receptor-engagement compounds) from compound-specific contraindication (to be established at FDA approval).

2.2 Inclusion criteria — the anticipated trial-enrolled and label-permitted phenotype

Inclusion criteria are stated as the population the TRIUMPH program enrolled and the anticipated post-approval label is anticipated to permit, anchored to each TRIUMPH trial’s enrollment criteria per ClinicalTrials.gov v2 API trial-registration records (Retatrutide canonical v1.0-final §3.3 trial roster).

Anticipated CWM (obesity / overweight) inclusion. Adults age ≥18 with BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, ASCVD, MASLD). This is the TRIUMPH-1 / TRIUMPH-9 enrollment scope and the anticipated post-approval CWM label scope (anchored to the typical Module 5 GLP-1 RA CWM label structure established by Wegovy 2.4 mg semaglutide and Zepbound tirzepatide).

Anticipated T2D inclusion. Adults age ≥18 with T2D, HbA1c typically 7.0–10.0% in TRIUMPH-2 / TRANSCEND-T2D enrollment scope, on background therapy per the specific trial protocol (diet and exercise alone for TRANSCEND-T2D-1; metformin with or without SGLT2 inhibitor for TRANSCEND-T2D-2; basal insulin with or without metformin / SGLT2 inhibitor in the moderate-severe renal impairment population for TRANSCEND-T2D-3).

Anticipated CV risk reduction inclusion. Adults with severe obesity + established cardiovascular disease (TRIUMPH-3 enrollment; primary completion 2026-04; ACTIVE_NOT_RECRUITING) or BMI ≥27 with ASCVD and/or CKD (TRIUMPH-Outcomes enrollment; n=10,000; primary completion 2029-02; ACTIVE_NOT_RECRUITING; event-driven MACE/MAKE composite). Effect-size anchors are Phase 3 readout-pending.

Anticipated obesity + knee OA inclusion. Adults with obesity / overweight + knee osteoarthritis (TRIUMPH-4 enrollment; COMPLETED 2025-11-14; sponsor-disclosed topline December 11, 2025: −28.7% body weight reduction at 12 mg vs placebo at 68 weeks; peer-reviewed primary publication PMID assignment pending as of 2026-05-13). The trial design rationale per Giblin 2026 PMID 41090431 links weight loss to mechanical-load relief plus potential systemic inflammation modulation.

Anticipated weight maintenance inclusion. Adults who have achieved initial weight loss and are continuing pharmacotherapy for weight maintenance (TRIUMPH-6 enrollment scope; n=643; primary completion 2028-04; ACTIVE_NOT_RECRUITING). Trial-design rationale addresses the chronic-obesity-pharmacotherapy weight-regain-after-discontinuation research direction.

Anticipated MASLD / MASH inclusion. Adults with MASLD (≥10% MRI-PDFF hepatic fat at baseline) in the Phase 2a MASLD substudy enrollment (Sanyal 2024 PMID 38858523; n=98) — this is the established Phase 2a evidence-base population. The anticipated Phase 3 MASLD scope emerges from the SYNERGY-Outcomes Phase 3 multi-agent master protocol (NCT07165028; n=4,500; primary completion 2030-08; RECRUITING).

Anticipated CKD-in-T2D inclusion. TRANSCEND-T2D-3 enrollment scope (moderate-severe renal impairment + basal insulin); also the renal-outcomes Phase 2 trial (NCT05936151; n=146; COMPLETED 2025-10-01) addressing renal-outcomes-effect research direction in overweight / obesity + CKD with or without T2D. Phase 3 CKD-outcomes data emerge from TRIUMPH-Outcomes (MAKE composite) and from TRANSCEND-T2D-3.

Trial-enrollment laboratory thresholds. Per the specific trial protocol — typically eGFR thresholds (TRIUMPH program protocols vary; TRANSCEND-T2D-3 enrolls moderate-severe renal impairment), hepatic-function thresholds (Child-Pugh class typically excluded for severe hepatic impairment), and hematologic thresholds. Specific thresholds verify against the trial-specific ClinicalTrials.gov record at active enrollment evaluation.

Pregnancy / lactation status. Pre-conception, not currently pregnant, on contraception if reproductive-age — TRIUMPH protocols define their specific contraception requirements. See §8 for the discontinuation-trigger half-life arithmetic.

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where retatrutide use is not contraindicated on mechanism grounds but where benefit is uncertain, risk is elevated, or trial data are sparse. Pattern V direction-of-effect: for under-represented phenotypes, expected effect-size may differ from trial-program-typical and is research-state-incomplete.

• Severe gastroparesis or gastroparesis-predisposing comorbidity. GLP-1R-mediated delayed gastric emptying is shared with the broader GLP-1 RA class; GIPR agonism contributes additional gastric-motility considerations; in established gastroparesis, anatomical and symptomatic worsening risk is elevated. TRIUMPH program enrollment criteria typically excluded severe gastroparesis. Relative-exclusion clinician-judgment posture.
• Active or recent (within 12 months) acute pancreatitis. Distinct from severe prior pancreatitis history (a hard contraindication per §2.4 per the class-level GLP-1 RA framework); recent acute pancreatitis is a relative-exclusion clinician-judgment posture.
• Severe gastrointestinal disease. Active IBD flare, severe GERD with esophagitis. Relative — the GI AE profile of retatrutide (anticipated to be GI-dominant per Phase 2 program safety reporting; Jastreboff 2023 PMID 37366315; Rosenstock 2023 PMID 37385280; Sanyal 2024 PMID 38858523) may exacerbate.
• Diabetic retinopathy with rapid-HbA1c-improvement risk. Class-level consideration — rapid HbA1c reduction is associated with transient worsening of diabetic retinopathy in pre-existing retinopathy populations. Retatrutide-specific phenotype-targeting consideration for the T2D-indication subpopulation; ophthalmology pre-screening for proliferative diabetic retinopathy or advanced background DR is the recommended posture.
• Severe renal impairment (eGFR <30 outside trial-enrolled range). Phase 1 renal impairment population pharmacokinetics characterized in NCT05611957 (n=29; COMPLETED 2023-09-05; primary publication may follow). TRANSCEND-T2D-3 enrolls moderate-severe renal impairment but the specific eGFR floor verifies against the trial-specific ClinicalTrials.gov record. eGFR <15 is outside any registered Phase 3 enrollment and lacks direction-of-effect verification (Pattern V applies).
• Severe hepatic impairment (Child-Pugh C). Phase 1 hepatic impairment population pharmacokinetics characterized in NCT05916560 (n=43; COMPLETED 2025-03-02). Severe hepatic impairment is a relative-exclusion clinician-judgment posture given the GCGR-agonism component operating on hepatic biology.
• Active eating disorder. Anorexia nervosa, bulimia nervosa, BED with active purging — the appetite-suppression mechanism is contraindicated in disordered eating; ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management.
• Active malignancy on therapy (other than the class-level MTC / MEN-2 contraindication per §2.4). TRIUMPH protocols typically excluded active cancer; clinician judgment with oncology co-management.

2.4 Hard contraindications — class-level boxed warnings (mechanism-grounded; retatrutide-specific contraindications to be established at FDA approval)

Hard contraindications applicable to retatrutide on mechanism-class grounds, with the explicit Pattern AA qualification that retatrutide-specific FDA-label contraindications will be established at FDA approval and may add to or refine this class-level inventory.

• Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for FDA-approved GLP-1 RAs (semaglutide, tirzepatide, liraglutide, dulaglutide) based on the foundational rodent C-cell mechanism finding (Bjerre Knudsen L, Madsen LW et al. Endocrinology 2010 Apr PMID 20203154); class-level human MTC signal is debated. The class-level contraindication is typically extended to the broader incretin-receptor-modulator class in clinical practice including the pre-approval triagonist class. Retatrutide-specific triagonist-class consideration: GLP-1R is the receptor implicated in the rodent C-cell signal; GIP receptor and glucagon receptor C-cell expression are research-state-incomplete; whether GIPR and GCGR agonism at retatrutide receptor-engagement depths modifies the GLP-1R-mediated C-cell signal in either direction is research-state-open (canonical §5.2). Class-level contraindication applies; retatrutide-specific contraindication characterization emerges from TRIUMPH calcitonin surveillance findings.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same class-level mechanism-grounded contraindication.
• Severe prior pancreatitis history. Class-level precaution / labeled cautionary use for FDA-approved GLP-1 RAs per their respective labels; class-level signal per Wen J, Nadora D et al. Endocrinol Diabetes Metab 2025 Sep PMID 40988099 (class-level SR + meta-analysis pancreatitis + pancreatic cancer). For retatrutide pre-approval, severe prior pancreatitis applies as a hard contraindication on mechanism-class grounds; retatrutide-specific framing emerges from TRIUMPH primary publications.
• Known serious hypersensitivity to retatrutide or formulation excipient. General principle applicable to any peptide therapeutic; retatrutide-specific hypersensitivity reporting from TRIUMPH primary publications.
• Pregnancy (for CWM and most anticipated metabolic indications). Class-level contraindication per the typical FDA labeling for GLP-1 RAs in CWM indication. For retatrutide pre-approval, pregnancy applies as a hard contraindication; TRIUMPH protocols define their contraception requirements for trial enrollment. Pregnancy is a §8 discontinuation trigger, not a §2 inclusion-screen-only criterion — a patient on protocol who becomes pregnant transitions out of protocol immediately.

2.5 Worked example — selection criteria applied to the §1.5 polycondition patient

The 54-year-old female from §1.5 (BMI 36, T2D HbA1c 8.4, prior MI 4 years ago, MASLD with FIB-4 2.1 and FibroScan 9 kPa, eGFR 64, UACR 145, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, post-menopausal, prior tirzepatide intolerance at 10 mg).

Inclusion criteria match. Her phenotype matches the anticipated TRIUMPH-2 (obesity + T2D) inclusion scope, TRIUMPH-3 (severe obesity + established CVD) inclusion scope, TRIUMPH-Outcomes (BMI ≥27 + ASCVD/CKD) inclusion scope, and SYNERGY-Outcomes (MASLD) inclusion scope. Per ClinicalTrials.gov v2 API status as of 2026-05-13: TRIUMPH-2 / -3 / -Outcomes are ACTIVE_NOT_RECRUITING (closed to new enrollment); SYNERGY-Outcomes is RECRUITING. If she is interested in active trial enrollment, SYNERGY-Outcomes is a candidate per her MASLD profile pending site availability; TRIUMPH-7 (obesity + chronic low back pain; RECRUITING) and TRIUMPH-9 (obesity / overweight without T2D extended; RECRUITING) are candidates per her remaining eligibility criteria pending site availability and the specific enrollment criteria for each trial.

Relative exclusion check. Her phenotype does not trigger any relative exclusion in §2.3 — no severe gastroparesis, no recent acute pancreatitis, no severe GI disease beyond standard, no proliferative diabetic retinopathy (she would receive dilated retinal exam per §3.3), her eGFR 64 is above the severe-renal-impairment threshold, her hepatic-function profile (MASLD with indeterminate-to-borderline-high fibrosis) is not severe hepatic impairment (Child-Pugh C), no active eating disorder, no active malignancy. Her prior tirzepatide intolerance is a Pattern V direction-of-effect signal — the GIPR-agonism component of retatrutide overlaps with the dual-incretin mechanism that produced her tirzepatide intolerance, suggesting the GIPR-related tolerability question is a research-state-incomplete clinician-judgment consideration; this does not exclude her but informs the §10 counseling beat and the §4 anticipated titration approach.

Hard contraindication check. No personal or family MTC, no MEN-2, no severe prior pancreatitis, no known retatrutide hypersensitivity (no prior retatrutide exposure), post-menopausal (pregnancy not applicable). She passes the §2.4 hard contraindication screen.

Pattern AA precision in §2.5. Every regulatory framing carries the appropriate qualification: “anticipated TRIUMPH-2 inclusion scope” (not “TRIUMPH-2 inclusion criteria” — the anticipated post-approval label scope is the anticipated-state qualification), “class-level contraindication on mechanism-class grounds” (not “FDA boxed warning for retatrutide” — retatrutide does not have an FDA label as of 2026-05-13). The class-level GLP-1 RA contraindications (MTC, MEN-2, severe pancreatitis history, hypersensitivity, pregnancy in CWM) apply on mechanism-class grounds and are anticipated to apply to retatrutide’s eventual FDA label; the specific compound-level retatrutide contraindications emerge from the FDA label at approval.

Pattern V cross-check at §2.5. Her prior tirzepatide intolerance is a Pattern V signal — the direction-of-effect for retatrutide tolerability in the dual-incretin-intolerant phenotype is research-state-incomplete. The TRIUMPH-5 head-to-head retatrutide vs tirzepatide trial (NCT06662383; n=800; primary completion 2026-12; ACTIVE_NOT_RECRUITING) will provide direct comparison data including tolerability; the question of whether dual-incretin-intolerant patients have differential retatrutide tolerability awaits Phase 3 readout. The relative-exclusion-vs-clinician-judgment posture for the GIPR-component-tolerability research question is documented per Pattern V discipline.

---

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before retatrutide initiation in the contexts where initiation is currently possible (TRIUMPH or TRANSCEND-T2D or SYNERGY-Outcomes trial enrollment; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathways exist), and the anticipated post-approval workup framework for clinical-education preparation.

Section 3 mirrors the Module 5 Protocol Template seven-panel structure (standard metabolic, diabetes-specific, MASH-specific, kidney-specific, CV-risk-specific, organ-baseline, body-composition baseline) with retatrutide-specific additions arising from the triagonist mechanism class — specifically, hepatic-biology surveillance considerations from the GCGR-agonism component (canonical §6.13) and cardiac glucagon-receptor expression / inotropic-effects research-state context from PMID 40613938 (canonical §6.6 + §6.13).

Pattern W cross-section consistency: every lab in §3.2–§3.8 is reconciled with the §5 maintenance monitoring intervals and the §6 AE management triggers. Pattern AB.4 standing scan: every NCT identifier and PMID is content-verified against the Retatrutide canonical v1.0-final.

3.2 Standard metabolic panel

Applies to every retatrutide initiation. Mirrors the Module 5 Protocol Template §3.2.

• Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-wide GLP-1 RA precautions and for the retatrutide-specific hepatic-biology surveillance arising from the GCGR-agonism component (§6.13 of the canonical develops the GCGR-driven fatty-acid mobilization framework that informs ALT/AST monitoring).
• Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk-indication eligibility (TRIUMPH-3 + TRIUMPH-Outcomes anticipated indication scope) and for monitoring metabolic improvement.
• Fasting glucose and HbA1c. Establishes glycemic baseline regardless of indication. For non-T2D obesity indication, this screens for undiagnosed prediabetes or T2D (which would inform the §1 indication category framing).
• Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference anchors visceral-adiposity-distribution phenotype targeting (§1.3).
• Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring (GLP-1 RA class SBP reduction is documented secondary effect; baseline BP context shapes hypertension co-medication adjustment).

3.3 Diabetes-specific panel (T2D indication)

Applies when retatrutide is being considered for T2D-anticipated indication (TRIUMPH-2 / TRANSCEND-T2D-1/-2/-3 scope) or when T2D is a comorbidity within a CWM / CV / MASH indication scope.

• HbA1c (above; standard panel). Confirms T2D diagnosis and severity. Phase 2 T2D enrollment (Rosenstock 2023 PMID 37385280) used HbA1c thresholds consistent with the Module 5 Protocol Template §3.3 enrollment scope.
• Fasting C-peptide. Establishes endogenous insulin reserve — distinguishes T2D from latent autoimmune diabetes of adults (LADA) and from advanced beta-cell-failure T2D where GLP-1 RA monotherapy response may be attenuated.
• GAD-65 and IA-2 antibodies (if LADA suspected). Adult-onset diabetes with normal BMI, rapid progression to insulin requirement, or atypical clinical course. GLP-1 RAs are not first-line in confirmed autoimmune diabetes; misclassification of LADA as T2D is a Pattern V direction-of-effect risk.
• Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also class-wide pre-treatment per §3.7), UACR for diabetic nephropathy, monofilament / vibratory testing for diabetic neuropathy.
• CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea. The retatrutide-specific Phase 1 hypoglycemia counter-regulatory response trial (NCT06982846; n=78; ACTIVE_NOT_RECRUITING) is the mechanism-specific research direction.

3.4 MASH-specific panel (MASH / MASLD indication or MASH risk profile)

Applies when retatrutide is being considered for MASLD / MASH-anticipated indication (SYNERGY-Outcomes Phase 3 multi-agent master protocol enrollment scope or extrapolation from the Phase 2a MASLD substudy) or when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT + waist circumference ≥102 cm men / ≥88 cm women). The retatrutide-specific Phase 2a MASLD substudy (Sanyal 2024 PMID 38858523; n=98) hepatic-fat-reduction magnitude (~82% MRI-PDFF reduction at 12 mg / 48 weeks) is the load-bearing pre-Phase-3 retatrutide MASLD evidence base.

• AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline. Retatrutide-specific consideration: the GCGR-mediated mobilization of hepatic fatty acids into mitochondrial β-oxidation is the mechanism component responsible for the Phase 2a MASLD substudy hepatic-fat-reduction magnitude (canonical §6.13); transaminase elevation surveillance during titration and maintenance is research-state-relevant.
• Platelet count. Component of FIB-4 calculation.
• FIB-4 score. Calculated non-invasive fibrosis score. Low <1.3, indeterminate 1.3–2.67, high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification. Standard MASLD non-invasive workup stratification.
• MRI-PDFF (where research-protocol pathway exists or clinical pathway available). The retatrutide-specific Phase 2a MASLD substudy used MRI-PDFF as the primary hepatic-fat-content endpoint; for retatrutide MASLD-indication use (anticipated post-approval and current SYNERGY-Outcomes Phase 3 trial enrollment), MRI-PDFF is the research-state-standard quantitative non-invasive hepatic-fat-content endpoint.
• Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
• Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis; elevated ferritin is common in MASH but very high transferrin saturation suggests iron-overload alternative.
• Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).

3.5 Kidney-specific panel (CKD indication or borderline baseline kidney function)

Applies when retatrutide is being considered for CKD-in-T2D anticipated indication (TRANSCEND-T2D-3 enrollment scope; renal-outcomes Phase 2 trial NCT05936151) or when baseline eGFR is 30–60 regardless of indication.

• Serum creatinine, eGFR. Standard renal-function baseline.
• Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture.
• Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria.
• Urinalysis with microscopy. Rules out alternative kidney disease.
• Renin-angiotensin system (RAS) blockade documentation. Standard background therapy for CKD-in-T2D context, anchored to the broader class-level evidence base.
• Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup; relevant for advanced CKD co-management.

3.6 CV-risk-specific panel (CVOT-anticipated indication or ASCVD risk profile)

Applies when retatrutide is being considered for CV-risk-reduction-anticipated indication (TRIUMPH-3 + TRIUMPH-Outcomes enrollment scope) or when baseline ASCVD risk profile is high regardless of indication.

• ECG (12-lead). Baseline rhythm and conduction status. Retatrutide-specific consideration: heart rate elevation is a known class-level effect (typically 2-4 bpm at therapeutic doses; PMID 41582189 addresses class-level heart-rate data in non-diabetic individuals including retatrutide). Cardiac glucagon-receptor expression and the inotropic-effects characterization in isolated human atrial preparations per PMID 40613938 (Naunyn Schmiedebergs Arch Pharmacol 2026 Jan) is research-state-active research direction; clinical-trial-population cardiac safety primary endpoints emerge from TRIUMPH-3 and TRIUMPH-Outcomes.
• High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD.
• NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60).
• Echocardiogram if HFpEF-suspect. LV ejection fraction, diastolic-function indices, LV-mass index.
• Carotid intima-media thickness or CAC score if subclinical ASCVD assessment is part of the practice’s CV-risk workflow.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs, with retatrutide-specific triagonist-class considerations)

Class-wide pre-treatment workup applicable to retatrutide on mechanism-class grounds, with retatrutide-specific triagonist-class considerations.

• Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. Personal or family history MTC / MEN-2 screening — hard contraindication per §2.4 on class-level mechanism-grounded basis. Class-level rodent C-cell signal foundational paper (Bjerre Knudsen 2010 PMID 20203154). Routine calcitonin screening is clinician-judgment, not protocol-mandated — class-level high false-positive rate without proportionate predictive value. Retatrutide-specific triagonist-class consideration per canonical §5.2: GIPR and GCGR C-cell expression are research-state-incomplete; TRIUMPH program protocol surveillance includes calcitonin monitoring per Giblin 2026 design paper PMID 41090431. Specific TRIUMPH program calcitonin surveillance findings emerge from Phase 3 primary publications.
• Pancreas baseline. Serum lipase, serum amylase (lipase is more pancreas-specific). Triglycerides (hypertriglyceridemic pancreatitis is a distinct etiology — addressed in §3.2). Pancreatitis-history documentation per §2.4. Class-level signal per Wen 2025 PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis).
• Ophthalmology — dilated retinal examination. Particularly for T2D patients per the §3.3 diabetes-complication-screen overlap. Class-level NAION signal per Lakhani M, Kwan ATH et al. Am J Ophthalmol 2025 Sep PMID 40383360 — multicenter observational pharmacovigilance study documented a NAION signal differentiated within the GLP-1 RA class: signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Retatrutide-specific NAION-signal characterization is research-state-pending the TRIUMPH Phase 3 ophthalmologic safety reporting. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation, not a labeled warning for retatrutide (retatrutide has no FDA label as of 2026-05-13). Pre-treatment ophthalmologic assessment is clinician-judgment, with particular relevance for patients with disc-at-risk anatomy, prior NAION, or unexplained visual symptoms.

3.8 Body-composition baseline

Applies to retatrutide initiation in CWM-anticipated indication and in any context where lean-mass preservation during weight loss is a clinical concern (older adults, athletic populations, high baseline lean mass).

• Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is more accurate; BIA more accessible.
• Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern. Retatrutide-specific consideration per canonical §6.13: chronic glucagon-receptor agonism is associated with potential catabolic effects on lean body mass (driven by glucagon-mediated amino-acid catabolism and gluconeogenic substrate supply); Phase 2/3 trial body-composition substudies inform the lean-mass-preservation evidence base, and the retatrutide calorie consumption Phase 1 trial (NCT06313528; n=85; COMPLETED 2025-08-26) addresses related mechanism-specific questions.
• Resting energy expenditure (REE) if indirect-calorimetry-equipped. Establishes energy-expenditure phenotype baseline. Retatrutide-specific consideration: the GCGR-mediated thermogenesis-via-futile-substrate-cycling mechanism component (canonical §2.3) may have differential effect-magnitude on REE; the relevant research-state-active research direction.

3.9 Worked example — pre-treatment workup applied to the §1.5 / §2.5 polycondition patient

For the 54-year-old female with BMI 36, T2D HbA1c 8.4, prior MI 4 years ago, MASLD with FIB-4 2.1 and FibroScan 9 kPa, eGFR 64, UACR 145, prior tirzepatide intolerance: pre-treatment workup comprises the full multi-panel inventory given her polycondition phenotype.

Standard metabolic panel (§3.2). CMP, fasting lipid panel, HbA1c (already documented at 8.4), weight / height / BMI / waist circumference, blood pressure.

Diabetes-specific panel (§3.3). Fasting C-peptide, dilated retinal exam given HbA1c 8.4 (within 6 months target for rapid-HbA1c-improvement-risk surveillance). UACR (already documented at 145). CGM data review if available.

MASH-specific panel (§3.4). AST/ALT/GGT/alkaline phosphatase/bilirubin, platelet count, FIB-4 (already calculated at 2.1 — indeterminate), VCTE (already documented at 9 kPa — borderline-high). MRI-PDFF — quantitative hepatic-fat-content baseline relevant for retatrutide-MASLD-indication consideration given the Phase 2a substudy magnitude (canonical §4.4) and for SYNERGY-Outcomes trial-enrollment evaluation. Hepatitis B/C screen and iron studies.

Kidney-specific panel (§3.5). UACR documented (145 — mild albuminuria). eGFR 64 — above the FLOW-style enrollment floor; documentation per §3.5. RAS-blockade status documentation (standard background therapy for CKD-in-T2D).

CV-risk-specific panel (§3.6). ECG given established ASCVD; troponin if symptomatic; echocardiogram if HFpEF-suspect. Lipid panel from §3.2.

Organ-baseline panels (§3.7). TSH, neck exam, pancreas baseline (lipase, amylase, triglycerides), pancreatitis-history documentation (negative). Ophthalmology dilated exam given HbA1c 8.4; NAION-context awareness per the class-context PMID 40383360 differentiation (signal documented for semaglutide; absent for tirzepatide; retatrutide-specific research-state-pending TRIUMPH Phase 3).

Body-composition baseline (§3.8). DEXA preferred over BIA for the polycondition phenotype with hepatic-IR-dominant component (DEXA quantifies visceral adipose tissue, which is the ectopic-fat-positive component of her phenotype). Hand-grip strength baseline.

Pattern W cross-check at §3.9. Every lab in this workup is reconciled with §5 maintenance monitoring intervals (HbA1c, UACR, eGFR, ALT/AST, lipid panel, body weight, BP, body composition, ophthalmology surveillance) and with §6 AE management triggers (ALT/AST surveillance per GCGR-component hepatic-biology framework; lipase if abdominal-pain symptom; calcitonin per TRIUMPH program design framework). The protocol explicitly states: lipase is monitored on symptom-prompted basis, not on scheduled-interval basis, consistent with the broader Module 5 protocol-discipline.

Pattern AB.4 standing scan applied to §3.9. Every PMID and NCT in this workup section has been content-verified against the Retatrutide canonical v1.0-final §6 + §11 verified-source inventory. PMID 41090431 is the Giblin 2026 TRIUMPH program design publication (Pub-type Journal Article only — design paper, not primary results — Pattern AB.4 framing); PMID 40383360 is the Lakhani 2025 NAION class-differentiation paper; PMID 41582189 is the heart-rate class-level paper including retatrutide; PMID 40613938 is the cardiac glucagon-receptor inotropic-effects paper; PMID 20203154 is the Bjerre Knudsen 2010 foundational C-cell paper; PMID 40988099 is the Wen 2025 pancreatitis + pancreatic cancer SR. All verified.

---

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for retatrutide initiation in the contexts where initiation is currently possible (TRIUMPH program trial-enrollment under trial protocol; clinician-judgment off-label investigational-supply use where research-protocol acquisition pathway exists), and the anticipated post-approval initiation framework for clinical-education preparation. Section 4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 16–20 (target-dose attainment per the Phase 2 obesity titration scope) — the period during which the patient transitions from naive to maintenance-stable.

Pattern AA discipline at this section: the titration schedules documented here are the Phase 2 trial-program titration schedules (Jastreboff 2023 obesity; Rosenstock 2023 T2D; Sanyal 2024 MASLD substudy) and the TRIUMPH Phase 3 program titration schedules documented in the Giblin 2026 design paper (PMID 41090431) and ClinicalTrials.gov protocol records. These are NOT label-recommended titration schedules because retatrutide has no FDA label as of 2026-05-13. Anticipated post-approval titration will likely follow the Phase 3 titration framework; specific label-recommended schedule will be established at FDA approval.

4.2 Starting dose

The retatrutide starting dose used across the Phase 2 program is 2 mg subcutaneous once weekly (per the Phase 2 obesity protocol per Jastreboff 2023 NEJM PMID 37366315 and the Phase 2 T2D protocol per Rosenstock 2023 Lancet PMID 37385280). This is the tolerability-priming starting dose; the purpose is GI-AE attenuation prior to escalation to the higher maintenance doses (8 mg or 12 mg) where the largest effect-size magnitudes are observed.

The Giblin 2026 TRIUMPH design paper (PMID 41090431 — design paper, NOT primary results — Pattern AB.4 framing discipline) documents the TRIUMPH-1 and TRIUMPH-4 starting dose framework; gradual escalation through 2 mg → 4 mg → 8 mg → maintenance doses with extended titration periods relative to the Phase 2 protocols, optimizing GI tolerability for the Phase 3 population. Specific TRIUMPH program titration schedules for other TRIUMPH trials verify against ClinicalTrials.gov v2 API trial-record protocol documents.

4.3 Titration schedule

Phase 2 obesity titration (Jastreboff 2023 NEJM PMID 37366315; NCT04881760). Multiple titration schedules were tested across the Phase 2 obesity protocol with starting doses and target maintenance doses. The 12-mg maintenance dose used in the most-effective Phase 2 obesity arm was reached via 12-week titration with 2-week intervals through 2 mg → 4 mg → 6-8 mg → 9-12 mg per the trial protocol arm structure. The most-effective Phase 2 obesity arm achieved up to −24.2% body weight reduction at 48 weeks (treatment-policy estimand), with 100% of the 12 mg arm achieving ≥5% body weight reduction.

Phase 2 T2D titration (Rosenstock 2023 Lancet PMID 37385280; NCT04867785). 281 adults with T2D were randomized across multiple dose arms versus placebo and active-comparator dulaglutide 1.5 mg over 36 weeks. The titration schedule and target doses varied across the Phase 2 T2D protocol; HbA1c and body-weight reductions across dose arms supported the dose-response framework.

Phase 2a MASLD substudy titration (Sanyal 2024 Nat Med PMID 38858523; n=98 MASLD substudy of NCT04881760). The MASLD substudy used the same Phase 2 obesity titration framework; the 12 mg dose arm achieved approximately −82.4% relative reduction in MRI-PDFF liver fat content at 48 weeks with 86% achieving normal liver fat (<5%).

TRIUMPH Phase 3 titration framework (Giblin 2026 PMID 41090431 design paper). Gradual escalation through 2 mg, 4 mg, 8 mg to maintenance doses with extended titration periods optimizing GI tolerability for the Phase 3 population. The specific dose-escalation intervals are typically every 4 weeks rather than every 2 weeks, prolonging the titration window relative to the Phase 2 protocols.

Anticipated post-approval titration framework. The post-approval titration framework will likely follow the Phase 3 titration design — gradual 4-week-interval escalation through 2 mg → 4 mg → 8 mg → maintenance doses. The specific label-recommended titration schedule will be established at FDA approval. Pattern AA precision: this is anticipated post-approval framework; label-recommended specifics emerge from the FDA label at approval.

Slow-titration option for tolerability. For patients with persistent moderate-severity GI AE at any titration step, the titration interval extension (typically doubling the interval at the challenging step) is the clinician-judgment tolerability adjustment within the trial-program tolerability framework. The trial-program titration schedules already incorporate gradual escalation for GI tolerability optimization; further extension is patient-specific tolerability adjustment.

4.4 GI tolerability management at each titration step

Retatrutide GI AE profile per Phase 2 program safety reporting (Jastreboff 2023 obesity; Rosenstock 2023 T2D; Sanyal 2024 MASLD substudy) is dose-dependent and dominated by nausea, vomiting, diarrhea, and constipation — the GLP-1 RA class-typical GI AE profile with retatrutide-specific dose-by-dose tolerability characterization through the Phase 2 program reporting. The AE profile peaks at each dose escalation and typically attenuates within 2-4 weeks at a stable dose, consistent with the broader GLP-1 RA class.

• Nausea — first-line non-pharmacologic. Reduce meal size, slow eating pace, avoid greasy / high-fat meals, hydrate consistently.
• Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea. Cross-reference with QT considerations in concurrent medications. The retatrutide Phase 1 metoprolol-PK drug-drug-interaction trial (NCT06808802; n=30; COMPLETED 2025-04-15) addresses β-blocker pharmacokinetic interaction; the broader Phase 1 DDI trial in obese participants (NCT05445232; n=32; COMPLETED 2023-02-24) addresses class-context DDI considerations.
• Vomiting — assessment. Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe persistent localized abdominal pain, with lipase elevation) — §6.4 algorithm.
• Diarrhea / constipation. Bowel-pattern-specific management; constipation can become the dominant GI pattern at maintenance doses for some patients.
• Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration — hold at current dose for an additional 2–4 weeks before next escalation, or step down to prior dose if tolerability does not stabilize.

4.5 Early monitoring cadence

The early-monitoring cadence during the retatrutide initiation period mirrors the Module 5 GLP-1 RA framework: contact at Week 2 (post-first-dose tolerability check), Week 4–6 (after first titration step), Week 8–12 (mid-titration tolerability and adherence), Week 16–20 (target-dose attainment confirmation and §5 transition). For TRIUMPH program trial-enrollment patients, the trial protocol defines the specific monitoring schedule.

Contact modality (in-person vs telehealth vs message) is practice-specific or trial-protocol-specific. Escalation triggers: any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, suspected NAION, suspected hepatic transaminase elevation per the GCGR-component hepatic-biology surveillance framework (§6.13 of the canonical), or significant unintended weight loss → in-person evaluation within 48 hours.

4.6 Worked example — retatrutide initiation walkthrough (anticipated post-approval framework; current trial-enrollment framework)

A clinical-education walkthrough of retatrutide initiation for an adult initiating retatrutide for the anticipated CWM indication (post-approval state) or via active TRIUMPH trial enrollment (current state).

Starting dose. Retatrutide 2 mg subcutaneous once weekly. This is the tolerability-priming dose; sub-maintenance for effect-target purposes. The purpose is GI-AE attenuation prior to escalation.

Phase 2 obesity titration schedule (Jastreboff 2023 protocol framework). Weeks 1–2: 2 mg weekly. Weeks 3–4: 4 mg weekly. Weeks 5–8: 6-8 mg weekly (per the specific Phase 2 arm). Weeks 9–12: 9-12 mg weekly target dose. Total titration period: approximately 12 weeks to 12 mg target dose.

Anticipated Phase 3 / post-approval titration framework (Giblin 2026 PMID 41090431 design paper). Extended titration with 4-week intervals: Weeks 1–4: 2 mg weekly. Weeks 5–8: 4 mg weekly. Weeks 9–12: 8 mg weekly. Weeks 13 onward: 12 mg weekly target dose (or 8 mg maintenance dose per the specific anticipated label maintenance-dose option). Total titration period: approximately 12-16 weeks to maintenance dose, with extended dose-step stabilization compared to the Phase 2 protocol.

Tolerability management at each step. First-dose (2 mg, Week 1) GI AE profile: nausea is the most common early AE — typically mild and self-limited within 5–7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. Escalation to 4 mg is typically well-tolerated given the gradual dose-step. Escalation to 8 mg and to 12 mg are the steps where GI AE rebound is most commonly observed — clinician-judgment tolerability adjustment with extended interval at the challenging step is the standard response.

Retatrutide-specific GI AE consideration: the dose-by-dose AE characterization from the Phase 2 program shows that nausea, vomiting, diarrhea, and constipation rates increase across the dose range with peak frequencies at the higher dose arms (8 mg, 12 mg) consistent with the GLP-1 RA class dose-dependent GI AE pattern. Discontinuation rates due to GI AE in the Phase 2 obesity trial were dose-dependent.

Early monitoring cadence — anticipated post-approval framework. Week 2 (post-first-dose telehealth tolerability check), Week 5–6 (post-first-titration in-person or telehealth, with weight and BP), Week 9–12 (mid-titration weight + BP + tolerability + ALT/AST per the GCGR-component hepatic-biology surveillance framework), Week 16–20 (target-dose attainment — weight + BP + transition to §5 maintenance cadence). For T2D-anticipated-indication initiation, add HbA1c reassessment at Week 12–16.

Pattern V applied to §4.6. Effect-size anchors at retatrutide target dose (peer-reviewed Phase 2 evidence): Phase 2 obesity (Jastreboff 2023 NEJM PMID 37366315; NCT04881760) demonstrated up to −24.2% body weight reduction at 12 mg / 48 weeks under the treatment-policy estimand in non-diabetic obesity (100% of the 12 mg arm achieved ≥5%; 83% achieved ≥15%). Phase 3 effect-size (sponsor disclosure pending peer-reviewed publication): TRIUMPH-4 obesity + knee OA (NCT05931367; n=445; 68 weeks; Eli Lilly press release December 11, 2025) reported −28.7% body weight reduction at 12 mg vs placebo. Direction-of-effect is established at the Phase 2 evidence-base level; the Phase 3 effect-size and the specific dose-by-dose effect-magnitude relationships will be confirmed at peer-reviewed Phase 3 publication.

Pattern AA applied to §4.6. Every titration claim carries its qualification: the Phase 2 titration is anchored to peer-reviewed Phase 2 publications; the TRIUMPH Phase 3 titration framework is anchored to the Giblin 2026 design paper (PMID 41090431) and to ClinicalTrials.gov protocol records (design paper, NOT primary results — Pattern AB.4 framing). The anticipated post-approval titration is anticipated framework, not label-recommended specifics. Retatrutide does not have an FDA label as of 2026-05-13.

Pattern Z calibration at §4.6. The initiation framework is presented factually; no specific dose, schedule, or tolerability-management decision is steered. Trial enrollment is presented as one option; clinician-judgment off-label use of investigational supply is presented as another; preparation for anticipated post-approval initiation is presented as the clinical-education framing of this protocol. The patient and clinician decide within the available evidence and the available access pathways.

---

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the retatrutide protocol: anticipated maintenance dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). Section 5 is anticipatory clinical-education content for retatrutide because the protocol’s maintenance-phase application is in (a) active TRIUMPH program participant follow-up under trial protocol, (b) clinician-judgment off-label investigational-supply use, and (c) anticipated post-approval maintenance practice.

Pattern AA discipline at this section: the target doses, monitoring intervals, and dose-adjustment triggers documented here are anchored to the Phase 2 program evidence base and the anticipated TRIUMPH Phase 3 maintenance framework. These are NOT label-recommended specifics because retatrutide has no FDA label as of 2026-05-13.

5.2 Anticipated maintenance dose

The anticipated maintenance dose framework for retatrutide is built from the Phase 2 evidence base and the TRIUMPH Phase 3 design framework:

Phase 2 maintenance dose framework. The 12 mg dose is the most-effective Phase 2 obesity arm (Jastreboff 2023 NEJM PMID 37366315) — up to −24.2% body weight reduction at 48 weeks under treatment-policy estimand. The 8 mg dose is also a Phase 2 evidence-base maintenance dose with effect-size below the 12 mg arm but with potentially favorable tolerability for some patients. The Phase 2 T2D protocol (Rosenstock 2023 Lancet PMID 37385280) used multiple maintenance doses across the dose-response framework.

TRIUMPH Phase 3 maintenance dose framework. TRIUMPH-4 (NCT05931367) tested 12 mg as the maintenance dose with the sponsor-disclosed topline (−28.7% body weight reduction at 12 mg vs placebo at 68 weeks; Eli Lilly press release December 11, 2025; peer-reviewed primary publication PMID assignment pending). The broader TRIUMPH program design framework per Giblin 2026 PMID 41090431 documents the maintenance dose framework across TRIUMPH-1 and TRIUMPH-4; specific maintenance-dose options for each TRIUMPH trial verify against ClinicalTrials.gov v2 API protocol records.

Anticipated post-approval maintenance dose framework. The post-approval maintenance dose framework will likely include 8 mg and 12 mg dose options, with 12 mg as the higher-effect-size option and 8 mg as the tolerability-preferred option for patients where 12 mg is not tolerated. The specific label-recommended maintenance dose schedule will be established at FDA approval. Pattern AA precision: this is anticipated post-approval framework; label-recommended specifics emerge from the FDA label.

Per-indication maintenance dose considerations.

• CWM (obesity / overweight) anticipated indication. Target 12 mg per the Phase 2 obesity arm and TRIUMPH-4 framework; 8 mg as the tolerability-alternative.
• T2D anticipated indication. Target 12 mg per the Phase 2 T2D protocol; multiple dose options across the TRANSCEND-T2D program will inform the specific T2D-indication maintenance-dose framework.
• MASLD anticipated indication. Target 12 mg per the Phase 2a MASLD substudy (−82.4% MRI-PDFF reduction at 12 mg); the SYNERGY-Outcomes Phase 3 multi-agent master protocol design (NCT07165028) will inform the anticipated MASH-indication maintenance-dose framework.
• Knee OA anticipated indication. Target 12 mg per the TRIUMPH-4 framework; the WOMAC pain endpoint and the body-weight endpoint scaling will inform the anticipated knee-OA-indication maintenance-dose framework upon peer-reviewed publication.
• CV-risk-reduction anticipated indication. Maintenance dose per the TRIUMPH-3 and TRIUMPH-Outcomes design framework; specific dose-by-dose CV outcomes data emerge from the Phase 3 readouts.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase mirror the Module 5 GLP-1 RA framework with retatrutide-specific additions:

Quarterly during the first year on maintenance dose (Months 4, 7, 10, 13 from initiation, or quarterly from target-dose attainment): weight, BP, brief AE-and-adherence interview, body-composition reassessment (BIA or DEXA — particularly given the GCGR-component lean-mass research direction per canonical §6.13), HbA1c (if T2D-indication), ALT/AST (retatrutide-specific surveillance per the GCGR-driven fatty-acid mobilization framework — canonical §6.13).

Biannual thereafter for stable patients on maintenance dose with no AE escalation or non-response triggers.

Retatrutide-specific monitoring additions.

• ALT/AST surveillance. Per the GCGR-component hepatic-biology framework (canonical §6.13) — the GCGR-mediated mobilization of hepatic fatty acids into mitochondrial β-oxidation is the mechanism component responsible for the Phase 2a MASLD substudy hepatic-fat-reduction magnitude (Sanyal 2024 PMID 38858523). Transaminase elevation surveillance during titration and maintenance is research-state-relevant. Phase 3 surveillance data anchors the specific effect-size and AE-rate framing; pending peer-reviewed Phase 3 publication, surveillance practice is research-state-anchored to the Phase 2 program evidence.
• Body composition surveillance. Per the GCGR-component lean-mass research direction (canonical §6.13) — chronic glucagon-receptor agonism is associated with potential catabolic effects on lean body mass. DEXA at quarterly intervals during the first year on maintenance is the recommended surveillance posture; Phase 2/3 trial body-composition substudies inform the evidence base.
• Cardiovascular surveillance. Heart rate is monitored at clinic visits per the class-level heart-rate elevation framework (PMID 41582189 Eur J Med Res 2026 Jan 26 addresses class-level heart-rate data in non-diabetic individuals including retatrutide). The cardiac glucagon-receptor expression and inotropic-effects characterization per PMID 40613938 (preclinical work in isolated human atrial preparations) supports surveillance attention; the TRIUMPH-3 (severe obesity + CVD) and TRIUMPH-Outcomes (event-driven MACE/MAKE composite) Phase 3 trial cardiac safety primary endpoints will populate the human-trial-population cardiac safety evidence base.

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase is driven by three trigger categories:

Target-not-met (effect is sub-threshold for clinical benefit at current dose). For CWM-anticipated indication: <5% weight loss at 6 months on maintenance dose with documented adherence triggers transition to §7 non-response algorithm. For T2D-anticipated indication: HbA1c above individualized target (typically <7.0% for most adults per ADA/EASD) at 6 months on maintenance dose triggers consideration of dose escalation if not already at maximum or transition to §7 non-response algorithm.

Target-overshoot. Unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below a patient-defined floor) triggers dose-down consideration. For T2D-indication, hypoglycemia risk on concurrent insulin or sulfonylurea is the most common overshoot pattern; the typical response is titration-down of the concurrent agent rather than retatrutide.

AE-emergent. New or worsening AE that responds to dose reduction — persistent moderate-severity GI AE on maintenance dose that does not respond to symptomatic management is the most common dose-down trigger. Retatrutide-specific AE-emergent triggers from the GCGR-component framework: clinically-significant ALT/AST elevation during titration or maintenance triggers hepatology consultation and dose-by-dose reassessment per the canonical §6.13 surveillance framework.

Dose-adjustment options. Hold dose (maintain current), titrate up (move to next anticipated dose option if not already at maximum), titrate down (move to prior dose for tolerability), or transition to §7 non-response algorithm.

5.5 Worked example — maintenance walkthrough applied to the §1.5 / §2.5 / §3.9 polycondition patient

For the 54-year-old female from §1.5 with the polycondition phenotype, the maintenance walkthrough assumes she has either (a) enrolled in an active TRIUMPH trial under trial protocol or (b) is receiving anticipated post-approval retatrutide under clinician-judgment within informed-consent. Pattern AA precision: retatrutide is not FDA-approved as of 2026-05-13; this worked example is anticipatory clinical-education content.

Anticipated maintenance dose. Target 12 mg per the Phase 2 obesity and Phase 2a MASLD evidence base and the TRIUMPH-4 framework. Given her prior tirzepatide intolerance at 10 mg (§2.5 Pattern V signal), 8 mg may be the tolerability-preferred maintenance dose pending Phase 3 dose-by-dose tolerability characterization in the dual-incretin-intolerant phenotype subgroup. Patient-clinician shared decision-making within the Phase 2/3 evidence framework.

Monitoring intervals. Quarterly during the first year on maintenance: weight + BP + heart rate + HbA1c + ALT/AST + UACR + lipid panel + body composition (DEXA). Annual: lipid panel, UACR, FibroScan / MRI-PDFF (MASLD surveillance — anchored to her baseline MASLD profile from §3.9), ophthalmologic surveillance per the class-context NAION research-direction and her T2D status.

Dose-adjustment triggers — specific to this patient.

• Target-not-met (CWM context). <5% weight loss at Month 6 on maintenance dose with documented adherence triggers §7 non-response algorithm. Anchored to the Phase 2 obesity / TRIUMPH-4 effect-size expectation; her polycondition phenotype is represented in the TRIUMPH-2/-3 enrollment scope.
• Target-not-met (T2D context). HbA1c >7.0% at Month 6 on maintenance dose triggers consideration of dose escalation if not at 12 mg or transition to §7 non-response. Her baseline HbA1c 8.4 with prior dulaglutide is the starting context.
• Target-overshoot. Hypoglycemia risk on concurrent agents — if she has been on insulin or sulfonylurea before retatrutide initiation, those concurrent agents are dose-reduced or discontinued at retatrutide initiation. She is currently on metformin + dulaglutide; dulaglutide discontinuation at retatrutide initiation is the standard transition framework (within-class redundancy avoidance — §9.4 contraindicated combinations).
• AE-emergent (GCGR-component hepatic-biology). Given her MASLD profile (FIB-4 2.1, FibroScan 9 kPa, MRI-PDFF baseline), ALT/AST surveillance during titration and maintenance is the load-bearing AE-emergent monitoring point. The Phase 2a MASLD substudy hepatic-fat-reduction magnitude is the anticipated direction-of-effect at her phenotype; ALT/AST stabilization or improvement during maintenance is the anticipated pattern.

Pattern W cross-check at §5.5. Every monitoring lab is established as a baseline lab in §3.9 (her workup includes ALT/AST, UACR, lipid panel, body composition, ophthalmology); every AE-trigger lab in §6 is in the monitoring schedule (ALT/AST per GCGR-component; lipase on symptom-prompted basis per §6.4; calcitonin per TRIUMPH design framework if clinically indicated). Structural-count claim consistency: ten TRIUMPH trials + three TRANSCEND-T2D + SYNERGY-Outcomes (Pattern W locked at §1.2; consistent at §5.5).

Pattern Z calibration at §5.5. The maintenance framework is presented factually; the dose decision (8 mg vs 12 mg given her dual-incretin-intolerance signal), the trial-enrollment decision, and the off-label investigational-supply decision are patient-clinician shared decisions. The protocol presents the Phase 2/3 evidence base; the clinicians decide.

---

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the AE categories that apply to retatrutide. Section 6 mirrors the Module 5 Protocol Template AE-by-AE-class operational structure (GI, gallbladder, pancreatitis, NAION class-context, injection site, hypoglycemia-in-T2D-with-concurrent-agent) with retatrutide-specific additions arising from the triagonist mechanism class — specifically, glucagon-receptor-agonism-specific safety considerations per the canonical §6.13 framework.

Pattern R applies: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the Phase 2 program reporting — before management. Pattern V applies: when an AE-class signal is post-marketing class-context (e.g., NAION for the GLP-1 RA class) or research-state-pending (e.g., retatrutide-specific Phase 3 cancer-incidence surveillance), the protocol documents the signal status precisely and does not generalize signal direction beyond what is established.

6.2 GI AE class — the dominant AE class

Anticipatory framing. Retatrutide GI AE profile per Phase 2 program safety reporting (Jastreboff 2023 obesity PMID 37366315; Rosenstock 2023 T2D PMID 37385280; Sanyal 2024 MASLD substudy PMID 38858523): nausea, vomiting, diarrhea, constipation are the dominant AE categories — dose-dependent, with greater frequency in higher-dose arms (8 mg, 12 mg). The AE profile peaks at each dose escalation and typically attenuates within 2-4 weeks at stable dose, consistent with the broader GLP-1 RA class. The GLP-1R-mediated delayed gastric emptying contributes the dominant share; the GIPR-agonism component adds the dual-incretin gastric-motility considerations shared with tirzepatide; the GCGR-agonism component is mechanism-class-distinct at the GI receptor distribution. Phase 2 trial-population GI AE incidence rates verify against the specific Phase 2 publication; dose-related discontinuation rates increase with dose but the overall rate remains within the range observed for other GLP-1 receptor-agonist class compounds per canonical §6.1.

Identification. Patient-reported during early-monitoring contacts (§4.5) and maintenance visits (§5.3). Standardized severity grading via CTCAE: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1-2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea per standard dosing; osmotic laxative (polyethylene glycol) for constipation.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe persistent localized abdominal pain (assess for pancreatitis — §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (Pattern Z calibration: patient-anchored; protocol does not override patient preference for discontinuation).

6.3 Gallbladder and biliary AE class

Anticipatory framing. Gallbladder events (cholelithiasis, cholecystitis) with rapid weight loss are a known class-level adverse-event category for the GLP-1 RA therapeutic class; mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility (canonical §6.5). Retatrutide-specific gallbladder AE incidence reporting from Phase 2/3 primary publications; pending Phase 3 publications, surveillance practice anchors to the class-level evidence.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is first-line imaging; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic: surgical consultation; typical management is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs. Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy: clinician-judgment for protocol continuation vs alternative transition. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication.

6.4 Pancreatitis AE class

Anticipatory framing. Acute pancreatitis signal in the GLP-1 RA class is debated; class-level evidence per Wen J, Nadora D et al. Endocrinol Diabetes Metab 2025 Sep PMID 40988099 (pancreatitis + pancreatic cancer SR + meta-analysis). Retatrutide-specific pancreatitis-incidence data within the Phase 2 program reporting were collected at trial-protocol-defined surveillance points; pooled class-analysis data inclusion or separate retatrutide-specific reporting depends on Phase 3 readouts. Standard surveillance practice for the GLP-1 RA class includes lipase / amylase monitoring when clinically indicated and discontinuation if pancreatitis is suspected (canonical §6.4).

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class typically does not produce severe persistent localized pain.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue retatrutide pending evaluation.

Escalation triggers. Confirmed acute pancreatitis → hospitalization, supportive management per pancreatitis standard-of-care.

Discontinuation triggers. Confirmed acute pancreatitis attributable to retatrutide (alternative etiologies — gallstones, hypertriglyceridemia, alcohol — ruled out) → permanent discontinuation, transition to non-GLP-1 alternative if a Module 5 indication continues. Severe prior pancreatitis history is a §2.4 hard contraindication.

6.5 Ophthalmologic AE class — NAION class-context (research-state-pending for retatrutide-specific characterization)

Anticipatory framing. Non-arteritic anterior ischemic optic neuropathy (NAION) signal differentiated within the GLP-1 RA class per Lakhani M, Kwan ATH et al. Am J Ophthalmol 2025 Sep PMID 40383360 — multicenter observational pharmacovigilance study documented a NAION signal: signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Retatrutide-specific NAION-signal characterization is research-state-pending the TRIUMPH Phase 3 ophthalmologic safety reporting. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation; not a labeled warning for retatrutide (retatrutide has no FDA label as of 2026-05-13).

Diabetic retinopathy class-level consideration. Rapid HbA1c improvement is associated with transient worsening of diabetic retinopathy in pre-existing retinopathy populations (class-level consideration applicable to retatrutide on mechanism-class grounds).

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue retatrutide pending evaluation. Cross-reference with ESR/CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent discontinuation, ophthalmology co-management, consideration of contralateral-eye risk.

Discontinuation triggers. Confirmed NAION → permanent discontinuation regardless of indication continuation. The class-context Pattern V: NAION-signal direction within the GLP-1 RA class shows class-differentiation (semaglutide-positive; tirzepatide-negative per PMID 40383360); retatrutide-specific direction-of-effect is research-state-pending. Clinician judgment in patients with disc-at-risk anatomy, prior NAION, or unexplained visual symptoms.

6.6 Cardiovascular AE class — heart rate elevation + cardiac glucagon-receptor research-state context

Anticipatory framing. Heart rate elevation is a known class-level effect for the GLP-1 RA class (typically 2-4 bpm at therapeutic doses; PMID 41582189 addresses class-level heart-rate data in non-diabetic individuals including retatrutide). Retatrutide-specific consideration per canonical §6.6 + §6.13: cardiac glucagon-receptor expression and the inotropic-effects characterization in isolated human atrial preparations per PMID 40613938 (Naunyn Schmiedebergs Arch Pharmacol 2026 Jan) — the preclinical work documents inotropic effects of retatrutide at glucagon-receptor-active concentrations, supporting a research-state-active research direction on triagonist-mechanism cardiac safety.

Phase 3 cardiovascular safety evidence base. TRIUMPH-3 (NCT05882045; severe obesity + CVD; primary completion 2026-04; ACTIVE_NOT_RECRUITING) and TRIUMPH-Outcomes (NCT06383390; event-driven MACE/MAKE composite; n=10,000; primary completion 2029-02; ACTIVE_NOT_RECRUITING) will provide the human-trial-population cardiac safety primary-endpoint data.

Class comparator. SELECT semaglutide Phase 3 CV outcomes in obesity without diabetes (Lincoff AM, Brown-Frandsen K et al. NEJM 2023 Dec 14 PMID 37952131): MACE composite HR 0.80 (95% CI 0.72-0.90) at 39.8 mo median follow-up. SURMOUNT-MMO tirzepatide Phase 3 CV outcomes active.

Identification. Heart rate monitored at every clinic visit per §5.3. Symptomatic palpitations, exercise intolerance, dyspnea on exertion trigger CV workup.

First-line management. Asymptomatic heart rate elevation within the class-typical 2-4 bpm range: monitor, no specific intervention. Symptomatic heart rate elevation or new arrhythmia: ECG, cardiology consultation, dose-adjustment consideration.

Escalation triggers. New atrial fibrillation, new symptomatic arrhythmia, acute coronary syndrome workup if symptomatic.

Discontinuation triggers. Confirmed serious cardiac AE attributable to retatrutide → discontinuation with cardiology co-management; specific framing emerges from Phase 3 cardiac safety reporting and from the cardiac glucagon-receptor research direction.

6.7 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) are anticipated at rates consistent with the broader GLP-1 RA class (typically ~5% of patients on weekly subcutaneous administration). Lipohypertrophy can develop with site rotation failure.

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a §2.4 hard contraindication and triggers permanent discontinuation.

6.8 Hypoglycemia AE class (T2D-indication with concurrent insulin or sulfonylurea)

Anticipatory framing. Retatrutide as monotherapy is not anticipated to be hypoglycemia-inducing — the glucose-dependent insulin-secretion mechanism (GLP-1R + GIPR component) is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents. Retatrutide-specific consideration: the GCGR-agonism component contributes residual hepatic gluconeogenic effect at therapeutic doses, counterbalanced by concurrent GLP-1R + GIPR insulinotropic activity (canonical §6.13 + §12.1) — at the intentionally-attenuated GCGR potency (~5.8 nM EC50), the Phase 2 program glucose outcomes did not show clinically significant hyperglycemia at therapeutic doses (Jastreboff 2023 obesity; Rosenstock 2023 T2D; Sanyal 2024 MASLD substudy). Concurrent insulin or sulfonylurea introduces hypoglycemia risk; the typical Phase 2/3 protocol response is to reduce the concurrent agent’s dose at retatrutide initiation. The retatrutide Phase 1 hypoglycemia counter-regulatory response trial (NCT06982846; n=78; ACTIVE_NOT_RECRUITING) addresses this mechanism-specific question.

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia is not a retatrutide discontinuation indication; it is a dose-adjustment indication for the concurrent agent.

6.9 Pregnancy and lactation considerations (Pattern Z calibration anchor 3 — pregnancy framing leads with human research-state data, not regulatory caution)

Pattern Z anchor 3 application: this section LEADS with human pregnancy-exposure research-state data, not with pharmacokinetic arithmetic or regulatory contraindication framing.

Human pregnancy-exposure data — Parker CH, Slattery C et al. Diabetes Obes Metab 2025 Aug PMID 40329607. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size is limited and the exposures are from unplanned-pregnancy contexts (prospective planned-pregnancy exposure data remains an active research direction; the authors call for prospective pregnancy registries). Per Phase 4 AB.4 hygiene: this is a pooled regulatory-data review, NOT a registered systematic review with PRISMA discipline. For retatrutide specifically, human pregnancy-exposure data is structurally more limited than for semaglutide / tirzepatide because of the smaller exposed Phase 2/3 trial population and the pre-approval status; whether the Parker 2025 pooled analysis includes specific retatrutide trial-population unplanned-pregnancy cases is determined by the primary publication content.

Standard clinical practice when pregnancy occurs or is planned (factual framing, not steering):

• Discontinuation upon pregnancy awareness; retatrutide elimination half-life is approximately 6 days, with approximately 5 half-lives (~30 days) for substantial clearance to steady-state baseline. Approximately 60-day washout is the pharmacokinetic-plus-margin window.
• For planned pregnancies: plan ≥2-month washout before conception attempts to allow complete clearance, consistent with the class-level GLP-1 RA pre-conception planning framework.
• Counsel reproductive-age patients on contraception during treatment per TRIUMPH program protocol-specific contraception requirements.
• Lactation-exposure data is research-state-incomplete; retatrutide is not used during breastfeeding per class-level GLP-1 RA practice and pending retatrutide-specific labeling at FDA approval.

Animal data context. Reproductive toxicity studies in animals support the class-level Category X-equivalent contraindication framing for GLP-1 RAs in pregnancy. Animal data does not always translate to human teratogenicity profile; the Parker 2025 human pooled data shows reassuring early signal but is the load-bearing human evidence as of 2026-05-13.

Pattern Z anchor 3 compliance verification. This section LEADS with Parker 2025 human research-state data (“Incidence of congenital abnormalities appears relatively low”). Standard clinical practice framed as factual (“Discontinuation upon pregnancy awareness”), not steering (“Avoid in pregnancy”). Pharmacokinetic facts and animal-data + class-level Category X contraindication framing appear AFTER the research-state lead, scoped as factual context. This is the canonical Anchor 3 framing structure (verbatim sema §6.8 calibration).

6.10 Glucagon-receptor-agonism-specific safety considerations (retatrutide-specific; canonical §6.13 framework)

This subsection is structurally new vs the semaglutide and tirzepatide protocols. It reflects safety considerations unique to the GCGR-agonism component of the triagonist mechanism. Three considerations are research-state-active:

Glycemic dynamics from GCGR-mediated hepatic gluconeogenesis. At the intentionally-attenuated GCGR potency (~5.8 nM EC50 vs native glucagon’s higher potency), the GCGR-mediated gluconeogenic effect is offset by the concurrent GLP-1R and GIPR insulinotropic activity. The Phase 2 trial glucose outcomes (Jastreboff 2023 obesity; Rosenstock 2023 T2D; Sanyal 2024 MASLD substudy) did not show clinically significant hyperglycemia at therapeutic doses across the dose range tested. T2D-population glycemic dynamics in the Phase 3 program (TRIUMPH-2 + TRANSCEND-T2D) will provide the load-bearing dose-by-dose hyperglycemia surveillance data.

Hepatic transaminase elevation context from GCGR-driven fatty-acid mobilization. The GCGR-mediated mobilization of hepatic fatty acids into mitochondrial β-oxidation is the mechanism component responsible for the Phase 2a MASLD substudy hepatic-fat-reduction magnitude (Sanyal 2024 PMID 38858523). Transaminase elevation surveillance during titration and maintenance is research-state-relevant — Phase 2/3 trial protocols address this through ALT/AST monitoring at trial-protocol-defined surveillance points. Effect sizes and AE rates with PMID anchoring per Pattern V discipline emerge from Phase 3 publications.

Cardiac glucagon-receptor expression and inotropic-effects characterization. PMID 40613938 (Naunyn Schmiedebergs Arch Pharmacol 2026 Jan) documented inotropic effects of retatrutide in isolated human atrial preparations at glucagon-receptor-active concentrations. The preclinical work supports a research-state-active research direction on triagonist-mechanism cardiac safety; TRIUMPH-3 (severe obesity + CVD) and TRIUMPH-Outcomes (event-driven MACE/MAKE) Phase 3 trial cardiac safety primary endpoints will populate the human-trial-population cardiac safety evidence base. Section 6.6 of this protocol develops the surveillance posture.

Catabolic / lean-mass dynamics from sustained glucagon-receptor agonism. Chronic glucagon-receptor agonism is associated with potential catabolic effects on lean body mass (driven by glucagon-mediated amino-acid catabolism and gluconeogenic substrate supply). Phase 2/3 trial body-composition substudies inform the lean-mass-preservation evidence base; the retatrutide calorie consumption Phase 1 trial (NCT06313528; n=85; COMPLETED 2025-08-26) addresses related mechanism-specific questions. §5.3 monitoring framework includes body-composition surveillance (DEXA preferred) to track lean-mass trajectory during retatrutide use.

6.11 Cancer-context surveillance (class-level + triagonist-class-specific)

Cancer-context surveillance for retatrutide operates at the class level (GLP-1 RA class cancer-context literature per the 2026 systematic review Ko A, Chang YC et al. Ann Intern Med 2026 Feb PMID 41359966 covering 11 cancers + 2 conditions across certainty tiers) plus three triagonist-class-specific dimensions per canonical §5.9:

1. GIP receptor and glucagon receptor C-cell expression considerations layered on the GLP-1R-mediated rodent C-cell mechanism (Bjerre Knudsen 2010 PMID 20203154). Calcitonin monitoring per TRIUMPH program design framework (Giblin 2026 PMID 41090431) when clinically indicated; standard practice for personal or family history MTC / MEN-2 is class-level absolute contraindication (§2.4).
2. Hepatocellular carcinoma research-state context arising from the GCGR-agonism component on hepatocytes (canonical §5.6 develops). HCC-incidence data is research-state-pending Phase 3 program surveillance including SYNERGY-Outcomes Phase 3 MASLD multi-agent master protocol; the Phase 2a MASLD substudy was not load-bearing for HCC-incidence data (48 weeks in a non-cirrhotic MASLD population — too short and not in HCC-risk-elevated population). Standard age-appropriate HCC surveillance per general clinical practice (alpha-fetoprotein + abdominal imaging in cirrhosis or high-risk populations).
3. Weight-loss-confounding axis applied to all cancer contexts — weight loss alone has cancer-incidence implications that must be differentiated from any direct receptor-mediated cancer-biology effects.

Phase 3 TRIUMPH program cancer-incidence data will populate the retatrutide-specific cancer-incidence evidence base across cancer-context categories when published. Pattern AA precision: surveillance recommendations beyond what Phase 3 trial protocols document are clinician-judgment; this protocol does not prescriptively recommend retatrutide-specific cancer surveillance beyond the class-level framework and the Phase 3 protocol-defined surveillance points.

6.12 Worked example — AE management walkthrough for the §1.5 / §2.5 / §3.9 / §5.5 polycondition patient

For the 54-year-old female from §1.5 with the polycondition phenotype on anticipated retatrutide maintenance dose:

Scenario A — Persistent moderate GI AE at maintenance. Patient on retatrutide 8 mg (the tolerability-preferred maintenance dose given her prior tirzepatide intolerance at 10 mg per §2.5 Pattern V signal), Month 6 on target dose, presents with persistent moderate nausea (Grade 2, recurring 2-3 days after each weekly injection), early satiety, and 11 kg total weight loss from baseline (approximately 10% of starting weight, on-trajectory for Phase 2 obesity / TRIUMPH-4 effect-size anchor).

Protocol response. Anticipatory framing: this is within the Phase 2 / TRIUMPH program-typical AE profile at the 8 mg dose; the recurring 2-3-day post-injection pattern is consistent with the pharmacokinetic profile of weekly retatrutide (~6-day half-life). First-line management: meal-size and meal-composition reinforcement; consider scheduled (not just PRN) ondansetron for the 2-3-day-post-injection window. Reassessment at Month 7: if nausea remains Grade 2 and patient is on-trajectory, continue current dose; if Grade 2 nausea is unacceptable to patient (Pattern Z calibration: patient-preference-anchored), dose-down or hold escalation to 12 mg. The dose-decision is patient-clinician shared.

Scenario B — ALT/AST elevation (GCGR-component hepatic-biology surveillance). Patient on retatrutide 12 mg, Month 4 on target dose, with ALT increasing from baseline 38 U/L to 95 U/L and AST from 32 to 78 U/L; no symptoms; MRI-PDFF surveillance showing substantial hepatic-fat reduction from baseline (~70% relative reduction at Month 4 — anchored to the Phase 2a MASLD substudy effect-size direction).

Protocol response. Anticipatory framing per §6.10: GCGR-driven fatty-acid mobilization is the anticipated mechanism component contributing both the hepatic-fat-reduction (a desired effect in her MASLD context) and the transaminase elevation (a research-state-active surveillance consideration). Per the Phase 2a MASLD substudy evidence base, the hepatic-fat-reduction magnitude correlates with the GCGR-component mechanism activity. Distinguish protocol-related transaminase elevation (anticipated in the context of large hepatic-fat-content reduction) from alternative liver-disease etiology (viral hepatitis screen at baseline negative per §3.9; iron studies at baseline negative; no autoimmune liver-disease screen indication). Decision: hepatology consultation; continue retatrutide with weekly ALT/AST surveillance pending the Phase 3 evidence base for GCGR-component transaminase elevation framing. If ALT >5× ULN or symptomatic, discontinue pending evaluation.

Scenario C — NAION class-context vision change. Patient on retatrutide 12 mg, Month 8, develops acute painless monocular vision loss in left eye over approximately 24 hours. Ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR and CRP normal (excluding GCA). Diagnosis: NAION, left eye.

Protocol response. Discontinue retatrutide. Confirmed NAION → permanent discontinuation per §6.5. Ophthalmology co-management for fellow-eye monitoring. Module 5 indication continuation: retatrutide-specific NAION-signal characterization is research-state-pending Phase 3 ophthalmologic safety reporting; cross-class direction-of-effect is per PMID 40383360 class-differentiation (signal documented for semaglutide; absent for tirzepatide). Alternative-class options: tirzepatide (NAION-negative per class-context literature) is a candidate alternative; semaglutide (NAION-positive class-context) is a candidate alternative with explicit shared-decision-making on the class-context signal; non-GLP-1 weight-management approach is another option. The patient and clinician decide within the available class-context evidence.

Pattern AA precision in §6.12. “NAION class-context signal” is precise — class-level post-marketing pharmacovigilance differentiation per PMID 40383360; retatrutide-specific direction-of-effect is research-state-pending. Discontinuation upon confirmed NAION is clinician-judgment within the class-context signal framework, not labeled mandate. “Anticipated transaminase elevation in the GCGR-component hepatic-biology framework” is precise — research-state-active per canonical §6.13; Phase 3 evidence base is research-state-pending.

---

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when retatrutide’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). Section 7 mirrors the Module 5 Protocol Template diagnostic-and-decision branch structure: distinguish pseudo-plateau (apparent stall that is in fact normal-trajectory variation), from true plateau (legitimate response stall requiring intervention), from non-response (insufficient initial effect).

Pattern AA discipline: the non-response algorithm at this section operates against the Phase 2 program effect-size expectations (Jastreboff 2023 obesity −24.2% at 12 mg / 48 weeks; Rosenstock 2023 T2D HbA1c reductions across dose arms; Sanyal 2024 MASLD substudy −82.4% MRI-PDFF at 12 mg / 48 weeks) and the anticipated TRIUMPH Phase 3 trial-program-typical trajectories (TRIUMPH-4 sponsor-disclosed −28.7% at 12 mg / 68 weeks). Phase 3 trajectory characterization for individual TRIUMPH trials emerges at peer-reviewed primary publication; pre-Phase-3-publication, the algorithm anchors to Phase 2 trajectories with Pattern AA-precise sponsor-disclosure framing where applicable.

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in weight or HbA1c that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with fat-mass continued loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern (most weight-loss molecules show deceleration in Months 6-9 even on continued effective therapy). Pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the Phase 2 / Phase 3 trial-program-typical curve and identifying that the apparent stall is in fact on-trajectory.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2-3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on maintenance dose with effect substantially below the Phase 2 / Phase 3 trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in §10 counseling does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

Retatrutide-specific set-point consideration: the GCGR-mediated energy-expenditure-via-futile-substrate-cycling mechanism component (canonical §2.3) may shift the defended set-point through sustained increased basal energy expenditure — research-state-active research direction per canonical §9 Question 1 (glucagon receptor agonism + hepatic biology integrative thread) and Question 5 (mechanism-versus-weight-loss-confounding differentiation).

7.4 Decision tree for plateau / non-response

1. Confirm adherence. Missed doses, injection-technique issues. For retatrutide on trial-enrollment context: trial-protocol adherence per the specific trial protocol. For investigational-supply off-label context: sourcing-channel quality + reconstitution discipline (relevant for compounded retatrutide from research-chemical / gray-market sources — see §8.7 of the canonical for the operational characteristics framing).
2. Confirm trajectory-context. Plot the patient’s curve against the Phase 2 / Phase 3 trial-program-typical curve for their phenotype. Jastreboff 2023 Phase 2 obesity trajectories (12 mg arm: −24.2% at 48 weeks; the 25th-percentile trajectory at Month 6 anchors ~7-9% loss); TRIUMPH-4 sponsor-disclosed topline (−28.7% at 12 mg / 68 weeks; trajectory detail pending peer-reviewed publication). If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.
3. Confirm dose attainment. Is the patient on maintenance dose (8 mg or 12 mg per the §5.2 anticipated maintenance dose framework)? If not, complete titration to maintenance dose; reassess at Month 3 on maintenance dose.
4. Reassess phenotype. Does the patient’s clinical picture support a phenotype the Phase 2 / Phase 3 program enrolled (the §1.3 phenotype-taxonomy dimensions), or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect — for under-represented phenotypes, expected effect-size may be smaller, recalibrate target.
5. If true plateau / non-response confirmed at adequate observation window:
   • CWM context. Consider transition to FDA-approved alternative (tirzepatide SURMOUNT-1 −22.5% at 15 mg / 72 weeks; semaglutide STEP-1 −14.9% at 2.4 mg / 68 weeks) — Pattern V direction-of-effect framework. Pattern AA precision: retatrutide is pre-approval; transition decisions in current practice operate against the FDA-approved alternative landscape. Intensification of behavioral / nutritional / activity program rather than pharmacologic change is the effect-additive alternative (per the broader Module 5 evidence base, e.g., STEP-3 demonstrated behavioral intensification is effect-additive for semaglutide).
   • T2D context. Transition to tirzepatide (Mounjaro; SURPASS-2 head-to-head established tirzepatide as the higher-effect within-class T2D alternative); or add SGLT2 inhibitor; or add insulin per ADA/EASD progression algorithm. Future head-to-head data: TRIUMPH-5 retatrutide vs tirzepatide obesity (NCT06662383; primary completion 2026-12); TRANSCEND-T2D-2 retatrutide vs semaglutide T2D (NCT06260722; primary completion 2026-08) will provide direct retatrutide-vs-comparator data when published.
   • MASLD / MASH context. Phase 3 MASH outcomes characterization beyond the Phase 2a substudy is via SYNERGY-Outcomes (NCT07165028) and any TRIUMPH-program MASH-specific evidence base. FDA-approved alternative class context: semaglutide ESSENCE (PMID 40305708) FDA-approved indication-establishing for non-cirrhotic F2/F3 MASH; resmetirom (Madrigal) FDA-approved 2024 for non-cirrhotic F2/F3 MASH; tirzepatide SYNERGY-NASH Phase 2 (Loomba R, Hartman ML et al. NEJM 2024 Jul 25 PMID 38856224 — tirzepatide, NOT survodutide which is PMID 38847460) reported 62% MASH resolution at 15 mg vs 10% placebo; tirzepatide SURMOUNT-MASH Phase 3 directional MASH data; survodutide Phase 2 MASH (Sanyal AJ, Bedossa P et al. NEJM 2024 Jul 25 PMID 38847460 — survodutide, NOT tirzepatide) reported 62% MASH resolution at 6.0 mg vs 14% placebo. Pattern AB.1 PMID inversion-prevention discipline applied: PMID 38856224 is tirzepatide SYNERGY-NASH; PMID 38847460 is survodutide.
   • CV-risk context. CVOT-anticipated indication framework is event-reduction, not surrogate; individual-patient “non-response” framing is less applicable at the individual-patient level over short observation windows. Phase 3 readouts from TRIUMPH-3 + TRIUMPH-Outcomes will define the CV-event-reduction evidence base.
   • CKD context. FLOW-anchored framing class-context to retatrutide via TRANSCEND-T2D-3 + TRIUMPH-Outcomes MAKE composite; non-response framing applies at the long-horizon kidney-composite endpoint level, not at the surrogate-marker level over short windows.

7.5 Worked example — non-response walkthrough for the §1.5 / §2.5 polycondition patient

For the 54-year-old female on anticipated retatrutide 8 mg (tolerability-preferred dose given dual-incretin-intolerance signal), Month 6 on maintenance dose, with 3.5 kg total weight loss from baseline (~3% of starting weight) — below the Phase 2 obesity 25th-percentile trajectory at Month 6 (~7-9% loss) and below the 5%-at-Month-6 trajectory marker.

Algorithm walkthrough.

Step 1 — Adherence. Patient reports 100% adherence; trial-protocol adherence audit (if on TRIUMPH enrollment) or refill audit (if on investigational-supply off-label use) confirms no gaps. Adherence-confirmed pseudo-non-response ruled out.

Step 2 — Trajectory-context. Patient’s curve at Month 6 (3% loss) is below the Phase 2 obesity 25th-percentile trajectory at Month 6. Not on-trajectory at the 8 mg dose level. Anticipated direction-of-effect at the 12 mg dose (per Phase 2 −24.2% at 12 mg; TRIUMPH-4 sponsor-disclosed −28.7% at 12 mg) is higher effect-size, but her tolerability profile (prior tirzepatide intolerance at 10 mg; current 8 mg dose chosen for tolerability) makes 12 mg dose escalation a Pattern V direction-of-effect-vs-tolerability tradeoff.

Step 3 — Dose attainment. Patient is on 8 mg, not 12 mg. Dose escalation option: titrate to 12 mg with extended interval and aggressive tolerability management; reassess at Month 9 (3 months on 12 mg) for trajectory.

Step 4 — Phenotype reassessment. Patient is a 54-year-old female, BMI 36, polycondition (T2D + MASLD + ASCVD + CKD-borderline), post-menopausal, prior tirzepatide intolerance. Per the Phase 2 obesity enrollment, this phenotype is represented (BMI ≥30); polycondition phenotype is represented in TRIUMPH-2/-3/-Outcomes scope. Phenotype is anticipated-trial-enrolled; effect-size expectation per Phase 2 / TRIUMPH-4 / SURMOUNT-1 framework. Her prior tirzepatide intolerance is a Pattern V signal — the direction-of-effect for retatrutide tolerability and for retatrutide effect-size in the dual-incretin-intolerant phenotype is research-state-incomplete pending TRIUMPH-5 head-to-head data and subgroup analyses.

Step 5 — Non-response confirmed at 8 mg; CWM-context decision branches.

5a. Dose escalation to 12 mg. Trial-anchored direction-of-effect: 12 mg is the highest-effect dose per Phase 2 / TRIUMPH-4. Tradeoff: tolerability — her tirzepatide intolerance signal suggests dual-incretin GIPR-related tolerability concern. Patient-clinician shared decision-making on the tolerability-vs-effect tradeoff.

5b. Transition to alternative FDA-approved class. Tirzepatide is contraindicated by her prior intolerance signal (Pattern V). Semaglutide SURMOUNT-class comparator (SURMOUNT-5 head-to-head: semaglutide −13.7% vs tirzepatide −20.2% at 72 weeks per Aronne LJ et al. NEJM 2025 Jul 3 PMID 40353578). Effect-size expectation at semaglutide-class for her polycondition phenotype is below the Phase 2 / TRIUMPH-4 retatrutide expectation. Pattern Z calibration anchor 4 (multi-dimensional comparator framing) applied: weight magnitude is one dimension; CV outcomes (SELECT PMID 37952131 HR 0.80), MASH approved indication (ESSENCE PMID 40305708), CKD outcomes (FLOW PMID 38785209), NAION class-context (PMID 40383360), GI tolerability, route, cost are other dimensions. The patient and clinician weigh the multi-dimensional fact set.

5c. Intensification of behavioral / nutritional / activity program. Behavioral intensification is effect-additive (anchored to the broader Module 5 evidence base, e.g., STEP-3 demonstrated). For this patient with polycondition phenotype and prior tirzepatide intolerance, behavioral intensification before pharmacologic transition may be the lower-risk first move.

5d. Combination consideration. Within-Module-5 combination options per §9 — retatrutide + SGLT2 inhibitor for T2D + CKD context (mechanism-additive; well-supported by individual-agent CVOT and KOOT data). Retatrutide + insulin (advanced T2D context) per ADA/EASD progression framework.

Pattern Z calibration anchor 4 applied at §7.5. Multi-dimensional comparator framing presented; both retatrutide-class and FDA-approved alternative-class options framed factually; the patient and clinician decision-making is anchored to the multi-dimensional fact set, not steered toward any specific option. The patient-counseling beat: “Here’s where your trajectory is relative to what the trial program would predict. Here are the options — dose escalation, alternative-class transition, behavioral intensification, combination — with the effect-size and tolerability and access considerations for each. Let’s decide together which factors matter most for your situation.”

---

8. Discontinuation and tapering

8.1 Purpose

Define when to stop retatrutide, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory anticipated in CWM context. Section 8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

Pattern AA discipline at this section: the discontinuation triggers and the taper schedule documented here are anchored to (a) the class-level GLP-1 RA discontinuation framework applicable on mechanism-class grounds; (b) the Phase 2 program safety reporting evidence base; (c) the anticipated TRIUMPH-6 weight-maintenance Phase 3 trial evidence base (NCT06859268; n=643; primary completion 2028-04; ACTIVE_NOT_RECRUITING) — designed to address the chronic-obesity-pharmacotherapy weight-regain-after-discontinuation research direction.

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

• Confirmed contraindication discovery. New MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM-anticipated indication. §2.4 hard contraindications are immediate-discontinuation triggers.
• Severe AE attributable to retatrutide. Confirmed acute pancreatitis (§6.4); confirmed NAION class-context vision change (§6.5); severe hypersensitivity reaction; serious cardiac AE per §6.6; clinically-significant ALT/AST elevation that does not respond to dose-adjustment per §6.10 GCGR-component framework. Section 6 AE-class-specific discontinuation triggers.
• Indication remission or resolution. T2D HbA1c sustained below target with weight stable in some patients; MASH histologic resolution sustained; rare but documented in the broader GLP-1 RA class.
• Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision (Pattern Z calibration: patient-preference-anchored).
• Cost / access barriers. Particularly relevant for retatrutide pre-approval given the investigational-supply acquisition landscape and the pre-FDA-approval-compounded-retatrutide research-chemical / gray-market context (canonical §8.3.2 + §8.7). Pattern Z calibration anchor 1+2 framing: present access realities factually, not as steering. The pre-approval-compounded framing is structurally different from the post-FDA-approval 503A/503B compounded framing (see §10.3 for the protocol’s calibration).
• Pre-conception planning for reproductive-age patients. Discontinuation with approximately 60-day washout per the §8.4 arithmetic. Anticipatory discontinuation, not reactive.
• Trial-enrollment completion. For TRIUMPH program participants, trial-protocol-defined treatment-period completion triggers protocol-defined discontinuation; post-trial continuation depends on FDA approval status and investigational-supply availability.

8.3 How to taper — molecule-specific tapering considerations

For retatrutide in CWM-anticipated indication context: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule (~6-day half-life; ~30 days for substantial clearance). However, gradual dose reduction is the anticipated recommended pattern for two reasons consistent with the broader GLP-1 RA class framework:

1. Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation (the patient’s reduced appetite signal returns gradually, allowing meal-size and meal-composition adaptation in parallel).
2. AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

Anticipated retatrutide taper pattern for CWM context. 12 mg → 8 mg for 4 weeks → 4 mg for 4 weeks → 2 mg for 4 weeks → discontinue. Total taper period approximately 12 weeks. This is anticipated framework; specific label-recommended taper schedule will be established at FDA approval, if any. Pattern AA precision: this is anticipated framework, not label-recommended specifics. Retatrutide does not have an FDA label as of 2026-05-13.

8.4 Pre-conception washout arithmetic — retatrutide

Retatrutide elimination half-life is approximately 6 days (Urva S, Coskun T et al. Lancet 2022 Nov 26 PMID 36354040 Phase 1b multiple-ascending-dose pharmacokinetics in T2D). Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 30 days. With a conservative pharmacodynamic margin for the receptor-engagement-and-physiological-response window, the anticipated pre-conception discontinuation recommendation is ≥2-month washout before planned conception. This is consistent with the class-level GLP-1 RA pre-conception planning framework (e.g., semaglutide ~1-week half-life with ~8-week label recommendation; tirzepatide ~5-day half-life with similar margin).

The 60-day arithmetic operationally translates to: discontinue retatrutide at least 8 weeks before planned conception attempts. This is the operational counseling beat for reproductive-age patients on retatrutide CWM-anticipated indication — §10 counseling beats anchor to this arithmetic with Pattern Z calibration anchor 3 (pregnancy planning) precision (LEADING with human research-state data per §6.9, not with PK arithmetic).

8.5 Post-discontinuation weight-regain framing

The class-level GLP-1 RA evidence base on post-discontinuation weight regain (e.g., STEP-4 semaglutide, SURMOUNT-4 tirzepatide) demonstrates that discontinuation after target-dose achievement is followed by progressive weight regain across approximately 12 months, with patients regaining a substantial fraction of the lost weight by 12 months post-discontinuation. The mechanism — set-point physiology and the defended-weight biology (§7.3) — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium.

Retatrutide-specific weight-maintenance evidence base. TRIUMPH-6 (NCT06859268; n=643; weight reduction maintenance; primary completion 2028-04; ACTIVE_NOT_RECRUITING) is the retatrutide-specific weight-maintenance Phase 3 trial. Effect-size on the maintenance-phase trajectory and on the post-discontinuation regain trajectory emerges from this Phase 3 readout. Pending Phase 3 publication, the protocol framing anchors to the broader GLP-1 RA class evidence base.

The protocol framing in §10 counseling does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention. Patients considering discontinuation are counseled on the expected regain trajectory and on the re-initiation pathway if regain occurs and warrants re-treatment.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: re-titration from the starting dose (2 mg) is the anticipated recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior maintenance dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — discontinuation scenarios for retatrutide

Scenario A — pre-conception planning. A 34-year-old female on anticipated retatrutide 12 mg, Month 18 on maintenance dose, has lost 22.5 kg (~22% of starting weight, on-trajectory for Phase 2 / TRIUMPH-4 effect-size anchor) and is planning conception in approximately 6 months. Counseling beat (Pattern Z anchor 3 — LEADS with Parker 2025 PMID 40329607 human research-state data per §6.9 framing): the pooled regulatory pregnancy-exposure data shows reassuring early signal; sample size limited; planned-pregnancy exposure data is research-state-incomplete. Plan taper start approximately 4-5 months from now (12-week taper period, then approximately 60-day post-discontinuation pharmacokinetic-plus-margin window). The patient’s reproductive-planning decision is patient-anchored; the counseling presents facts.

Scenario B — patient-preference discontinuation. A 58-year-old male on anticipated retatrutide 12 mg, has lost 18 kg (~18% of starting weight) and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss class-level post-discontinuation trajectory data (substantial fraction of lost weight typically regained by 12 months post-discontinuation across the GLP-1 RA class); TRIUMPH-6 retatrutide-specific weight-maintenance evidence base is research-state-pending Phase 3 publication; re-initiation pathway is available if regain occurs. Protocol taper: 12 mg → 8 mg × 4 weeks → 4 mg × 4 weeks → 2 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit if regain warrants and patient agrees.

Scenario C — confirmed acute pancreatitis (per §6.4 framework). Permanent discontinuation. No taper — abrupt discontinuation appropriate given the AE-attributable etiology. Transition to non-GLP-1 alternative per indication; FDA-approved alternatives in the class are also class-level pancreatitis-precaution per the broader GLP-1 RA class — clinician-judgment within informed consent.

Scenario D — new pregnancy on protocol. A 29-year-old female on anticipated retatrutide 12 mg discovers pregnancy at approximately 6 weeks gestation. CWM-anticipated-indication retatrutide applies the class-level pregnancy-contraindication framework per §2.4. Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (~30 days, with first-trimester exposure already occurred) is documented for the obstetrics record. Class-level Parker 2025 PMID 40329607 pooled regulatory pregnancy-exposure data shows reassuring early signal across the broader GLP-1 RA class; retatrutide-specific exposure data is research-state-limited given the smaller Phase 2/3 trial population. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication and pending retatrutide regulatory status at the time of consideration.

Scenario E — trial-enrollment completion. A 45-year-old female who completed the TRIUMPH-2 study (obesity + T2D; n=1,000; primary completion 2026-05; ACTIVE_NOT_RECRUITING) and her treatment-period has concluded per trial protocol. Post-trial continuation depends on retatrutide regulatory status at the time of trial conclusion — if retatrutide is approved by the time of her trial-period completion, transition to commercial supply per the approved indication is the operational pathway; if retatrutide is still pre-approval at her trial-period completion, the options are (a) trial-extension study participation if available, (b) anticipated-approval-awaiting period with documented weight and metabolic trajectory monitoring, (c) transition to FDA-approved alternative class (tirzepatide / semaglutide) per the Pattern Z anchor 4 multi-dimensional comparator framing of §10.5.

Pattern Z calibration anchor 3 precision in §8.7 Scenario A. The pre-conception counseling LEADS with the Parker 2025 human research-state data, not with PK arithmetic. PK facts and class-level Category-X-equivalent framing appear AFTER the research-state lead. Post-discontinuation weight-regain trajectory presented as factual context, not as steering toward continued pharmacotherapy. Pregnancy-exposure framing presented as factual context, not as steering toward immediate discontinuation. The patient’s decision is patient-anchored.

Pattern AA precision in §8.7. Every regulatory framing carries its qualification: retatrutide is anticipated-indication (pre-approval as of 2026-05-13); discontinuation triggers are anchored to mechanism-class grounds plus the canonical §6 AE-class framework; the taper schedule is anticipated framework, not label-recommended specifics; the re-initiation pathway is anticipated framework. The §8.7 Scenario E “post-trial continuation” framing explicitly addresses the pre-approval state where trial-period completion creates a specific operational gap.

---

9. Combination rules

9.1 Purpose

Define what stacks with retatrutide, what is contraindicated in combination, and the rationale for each combination category. Section 9 is anticipatory clinical-education content for retatrutide because the protocol’s combination-rule application is in (a) active TRIUMPH program participant follow-up where trial protocols define combination-permitted concurrent therapies; (b) clinician-judgment off-label investigational-supply use; and (c) anticipated post-approval combination practice.

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors). Pattern AA discipline: combination claims carry their epistemic-status qualification — Phase 3 evidence-base supported vs class-level mechanism-supported vs clinician-judgment within informed-consent.

9.2 Within-Module-5 combinations

The principal within-Module-5 combinations involve combining mechanism classes within the metabolic axis:

• Retatrutide + SGLT2 inhibitor (T2D / CKD / ASCVD context). Class-additive HbA1c and cardiovascular / kidney benefits; mechanism-additive (SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects). For the T2D + CKD or T2D + ASCVD polycondition context, retatrutide + SGLT2 inhibitor is mechanism-additive and well-supported by individual-agent CVOT / KOOT data for the SGLT2 class (EMPA-REG, CANVAS, DECLARE, DAPA-CKD, EMPA-KIDNEY) and the anticipated retatrutide CV/kidney evidence base from TRIUMPH-3 + TRIUMPH-Outcomes + TRANSCEND-T2D-3.

• Retatrutide + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where retatrutide monotherapy is insufficient. §6.8 hypoglycemia management applies; concurrent insulin dose typically reduced ~20% at retatrutide initiation per the broader GLP-1 RA class framework. Retatrutide-specific Phase 1 hypoglycemia counter-regulatory response trial (NCT06982846; ACTIVE_NOT_RECRUITING) addresses the mechanism-specific question.

• Retatrutide + metformin (T2D). Standard background therapy for T2D-anticipated indication; TRANSCEND-T2D-2 (NCT06260722) enrolls patients on metformin with or without SGLT2 inhibitor.

• Retatrutide + DPP-4 inhibitor: not indicated. Mechanistic overlap (DPP-4 inhibitor preserves endogenous GLP-1; redundant with the exogenous GLP-1R + GIPR + GCGR triagonist mechanism) makes the combination not clinically additive. Avoid co-prescribing.

• Retatrutide + sulfonylurea. Combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at retatrutide initiation per §6.8 hypoglycemia framework.

Within-class mechanism-overlap considerations (Pattern Z anchor 4 framing for transitions).

• Retatrutide + concurrent semaglutide or tirzepatide: contraindicated. These are within-class mechanism-redundant agents (semaglutide single GLP-1R; tirzepatide dual GLP-1/GIP; retatrutide triagonist GLP-1/GIP/glucagon — all three engage GLP-1R; retatrutide + tirzepatide additionally co-engage GIPR). Transition between agents (§7 non-response algorithm), not co-administration. Effect-size context per §10.5 multi-dimensional comparator framing.

• Retatrutide + survodutide or mazdutide or pemvidutide (GLP-1/glucagon dual agonists): contraindicated. Mechanism-redundant on the GLP-1R + GCGR axis; the triagonist (retatrutide) and the dual GLP-1/glucagon (survodutide / mazdutide / pemvidutide) are within-class mechanism-overlap. Transition framework applies.

• Retatrutide + MariTide (bispecific anti-GIPR + GLP-1R agonist) — mechanism-opposite GIPR-direction; research-state-novel. Pattern V direction-of-effect: MariTide antagonizes GIPR while retatrutide agonizes GIPR — opposite GIPR-direction bets within incretin-class development (canonical §2.5 + §7.4). Co-administration is mechanism-opposite at the GIPR axis; no clinical-trial data supports the combination. Clinical-practice rule: do not co-administer. Cross-class transition (retatrutide ↔︎ MariTide) follows the §7 non-response framework with Pattern V research-state-incomplete framing.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 RA / amylin / GIP / glucagon metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss. Retatrutide-specific consideration per canonical §6.13: chronic glucagon-receptor agonism is associated with potential catabolic effects on lean body mass; cross-Module lean-mass-stack consideration is particularly relevant for retatrutide given the GCGR-component lean-mass research direction.

• Retatrutide + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, IGF-1-anchored monitoring, and AE-class considerations. Pattern Z anchor 5 (off-label / extrapolation transparency) applies — CJC-1295 and Ipamorelin are not FDA-approved for the lean-mass-stack indication; the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

• Retatrutide + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA precision: do not state “approved” for an investigational peptide.

• Retatrutide + Tesamorelin (FDA-approved for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with retatrutide-mediated weight loss + GCGR-mediated thermogenesis component, visceral-adiposity-targeted effects are additive. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use. Pattern AA precision: the off-label-for-non-HIV-visceral-adiposity framing is explicit, not implicit; off-label use is clinician-judgment within informed-consent and primary-source-supported clinical reasoning.

• Retatrutide + GHK-Cu (skin / connective-tissue peptide). Cross-Module — GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. Pattern V direction-of-effect: GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations.

9.4 Contraindicated combinations

• Retatrutide + DPP-4 inhibitor (§9.2 — not clinically additive; avoid co-prescribing).
• Retatrutide + concurrent semaglutide, tirzepatide, or other GLP-1R/GIPR/GCGR-engaging compound (within-class mechanism-redundant; transition between agents, not co-administration).
• Retatrutide + MariTide (mechanism-opposite GIPR-direction; co-administration is research-state-novel without evidence support; do not co-administer).
• Retatrutide + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at retatrutide initiation per §6.8).
• Retatrutide + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).

9.5 Worked example — combination scenarios for retatrutide

Scenario A — retatrutide + SGLT2 inhibitor for the §1.5 polycondition patient. A 54-year-old female with T2D + ASCVD + CKD-borderline + MASLD on anticipated retatrutide 8 mg (tolerability-preferred dose), HbA1c 7.6 (improved from baseline 8.4 but above target 7.0); add empagliflozin 10 mg daily per ADA/EASD T2D-progression algorithm. Combination is well-supported by individual-agent CVOT / KOOT data for the SGLT2 class and by the anticipated retatrutide CV/kidney evidence base. Monitoring: eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5.3. Pattern V direction-of-effect: combination is effect-additive on HbA1c, on kidney composite, and on CV events per individual-agent data; cross-class combination is supported by mechanism rationale plus class-level evidence base, not by retatrutide + SGLT2 head-to-head combination RCT (Phase 3 retatrutide + SGLT2 combination evidence emerges from the broader TRIUMPH program subgroup analyses where applicable).

Scenario B — retatrutide + CJC-1295/Ipamorelin lean-mass stack (M5.6 v3). A 49-year-old male, baseline BMI 36, on anticipated retatrutide 12 mg, Month 8 on maintenance dose, has lost 19 kg with DEXA showing approximately 32% of lost mass as lean mass (above the 20-25% typical proportion for unsupplemented weight loss; the elevated lean-mass-loss proportion is research-state-consistent with the GCGR-component lean-mass-catabolism research direction per canonical §6.13). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — counseling beat states explicitly that CJC-1295 and Ipamorelin are not FDA-approved for this indication; retatrutide is pre-FDA-approval; the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario C — retatrutide ↔︎ tirzepatide transition (contraindicated co-administration). A patient seeking dual-class metabolic intensification asks about adding tirzepatide to retatrutide. Counseling beat: combination not indicated — these are within-class mechanism-overlap agents (both engage GLP-1R; both engage GIPR; retatrutide additionally engages GCGR); transition between them is the appropriate clinical decision, not co-administration. Effect-size context per §10.5 multi-dimensional comparator framing: Phase 2 obesity retatrutide −24.2% at 12 mg / 48 weeks; TRIUMPH-4 sponsor-disclosed Phase 3 retatrutide −28.7% at 12 mg / 68 weeks (peer-reviewed primary publication pending); SURMOUNT-1 tirzepatide −22.5% at 15 mg / 72 weeks; SURMOUNT-5 head-to-head tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks (Aronne 2025 NEJM PMID 40353578). Head-to-head retatrutide vs tirzepatide data emerges from TRIUMPH-5 (NCT06662383; primary completion 2026-12).

Pattern W cross-check at §9.5. Each combination above is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

---

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content for retatrutide — the conversations the clinician has with the patient at each protocol phase. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors are verbatim examples from semaglutide v1.0-final (Sections 8.3.2, 12.10-Pattern-2, 6.8, 12.10-Pattern-6, 12.10-Pattern-8), established as the calibration baseline post-iteration-4 verification on 2026-05-11. The canonical source — including the verbatim anchor text and the verbatim anti-anchor examples that failed Pattern Z — is /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. The five anchors:

• Anchor 1 — Compounded-formulation operational characteristics. LEADS with what compounded option IS (real-world clinical option used by substantial patient population; 503A / 503B pathways); operational characteristics framed neutrally; differences from FDA-approved framed as “factual scope, not deficit framing.” Retatrutide-specific calibration: Anchor 1 is structurally adapted for the pre-FDA-approval state — compounded retatrutide operates outside the post-FDA-approval 503A/503B framework (canonical §8.3.2 + §8.7); see §10.3 for the retatrutide-specific calibration.
• Anchor 2 — Compounded vs FDA-approved patient-counseling beat. Retatrutide-specific calibration: Anchor 2 is essentially N/A pre-approval — no FDA-approved retatrutide formulation exists to compare compounded against. The conversation reframes as investigational-supply-acquisition framing for trial-enrollment vs gray-market / research-chemical-vendor framing for off-label use; see §10.3.
• Anchor 3 — Pregnancy section research-state-leading structure. LEADS with human pregnancy-exposure data (Parker 2025 PMID 40329607), not PK arithmetic or label-status. See §10.4.
• Anchor 4 — Multi-dimensional comparator framing. Multi-dimensional fact presentation across 8+ dimensions for the comparator conversation. See §10.5.
• Anchor 5 — Off-label / extrapolation framing. Retatrutide-specific calibration: §10.6 is the dominant subsection for retatrutide. Because retatrutide has no FDA approval as of 2026-05-13, every clinical use of retatrutide today is either (a) trial-enrollment under TRIUMPH program protocol, or (b) off-label use of investigational supply with explicit informed-consent + research-state extrapolation transparency, or (c) gray-market / research-chemical-vendor compounded sourcing where the extrapolation transparency operates at the sourcing-channel quality layer in addition to the off-label-use layer.

Compound-specific counseling beats verify against verbatim canonical anchors. This section’s production includes a verbatim-diff check against the canonical anchor file at PSV iteration.

10.2 Initiation conversation (anticipated post-approval framework + current trial-enrollment / investigational-supply framework)

The initiation conversation occurs at pre-treatment workup completion / §4 initiation visit. Required counseling beats:

• What retatrutide is (Pattern AA-precise framing): a GLP-1 / GIP / glucagon triagonist in active Phase 3 development under the TRIUMPH program. Not FDA-approved as of 2026-05-13. Current access pathways: trial enrollment; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathway exists.
• What it does for the patient’s anticipated indication (Anchor 4 multi-dimensional framing): expected effect-size with Phase 2 trial-anchor precision (Jastreboff 2023 −24.2% at 12 mg / 48 weeks in non-diabetic obesity); TRIUMPH-4 sponsor-disclosed Phase 3 topline (−28.7% at 12 mg / 68 weeks; peer-reviewed primary publication pending); comparator framing if patient has alternative-class options.
• The titration schedule (§4): Phase 2 obesity titration framework (2 mg → 4 mg → 6-8 mg → 9-12 mg over ~12 weeks); anticipated TRIUMPH Phase 3 framework with extended 4-week intervals; patient is informed that the titration timeline is adjustable to their tolerability.
• The AE profile expected at each titration step (§6.2 GI class anticipatory framing): nausea is anticipated, typically attenuates, management strategies — non-pharmacologic first, ondansetron PRN second. Reassurance that AE-emergence is not failure but is anticipated. Retatrutide-specific addition: GCGR-component hepatic-biology surveillance (ALT/AST monitoring) is part of standard monitoring; transaminase elevation context per §6.10.
• The pre-conception planning beat for reproductive-age patients (Anchor 3 — LEADS with Parker 2025 human research-state data per §6.9): pharmacokinetic washout arithmetic (~6-day half-life; ~30-day clearance plus margin; ~60-day pre-conception window); the post-discontinuation weight-regain trajectory; the re-initiation pathway.
• Investigational-supply / sourcing realities (Anchor 5 — retatrutide-specific dominant calibration per §10.6): present investigational-supply pathways factually (trial enrollment; clinician-judgment off-label use of investigational supply via research-protocol channels); present gray-market / research-chemical-vendor framing factually for patients considering compounded retatrutide sources.
• What the patient signals back if any concern emerges (escalation pathway): symptoms that warrant in-person evaluation within 48 hours (severe persistent abdominal pain, vomiting blood, acute vision change per the §6.5 NAION class-context framework, signs of severe AE, suspected hepatic transaminase elevation).

10.3 Compounded-retatrutide counseling — Anchor 1 + Anchor 2 retatrutide-specific calibration (pre-FDA-approval state)

Retatrutide-specific calibration of Anchors 1 + 2. Because retatrutide has no FDA approval as of 2026-05-13, the canonical Anchor 1 framing (compounded option IS a real-world clinical option used by substantial patient population through 503A / 503B regulatory pathways) and the canonical Anchor 2 framing (compounded vs FDA-approved comparison) are structurally adapted for the pre-approval state.

What compounded retatrutide IS in the pre-FDA-approval state (factual research-state observation framing per canonical Methodology Adaptation Memo Q5 Option B; Pattern Z compliant — leads with what compounded retatrutide IS, not with what it isn’t):

Compounded retatrutide is a real-world phenomenon in the research-chemical and gray-market peptide-vendor channels. It is used by patients who (a) anticipate retatrutide’s FDA approval based on the TRIUMPH program readout schedule and want early access; (b) have a specific mechanism-class preference for the triagonist mechanism (GLP-1 + GIP + glucagon) over the single-GLP-1R (semaglutide) or dual GLP-1/GIP (tirzepatide) classes; (c) have prior non-response or intolerance to semaglutide and tirzepatide and are seeking the next within-class mechanism option ahead of approval; (d) participate in research-direction-tracking or peptide-research-community contexts where the early-access pathway through compounded sourcing is normalized.

Specific operational differences from the FDA-approved-formulation compounded landscape (factual scope, not deficit framing — per canonical §8.3.2 Option B):

• No FDA-declared shortage status applies because retatrutide has no FDA-approved indication to be in shortage of. The 503A (state-licensed pharmacy compounding) and 503B (FDA-registered outsourcing facility compounding) regulatory pathways that operate under shortage preconditions do not apply. Operational implication: the regulatory frame patients may be familiar with from compounded semaglutide / tirzepatide during the 2022-2024 shortage periods does not apply to compounded retatrutide.
• Sourcing-channel landscape differs. Compounded semaglutide and tirzepatide during the shortage periods could source active pharmaceutical ingredient from FDA-registered outsourcing facilities operating under 503B status. Compounded retatrutide sources from research-chemical vendors and gray-market channels — quality, purity, identity, and counterion-form variability is structurally greater than 503A/503B compounding. Operational implication: per-batch certificate of analysis review, sterility testing per USP standards where applicable, and sourcing-vendor reputation evaluation are more variable.
• Patient-population scope is structurally smaller than the compounded semaglutide / tirzepatide patient populations. Patients accessing compounded retatrutide are typically already familiar with the broader research-chemical / gray-market peptide market and have specific reasons for seeking retatrutide.
• No FDA-approved-sponsor-formulation comparator exists at the time of clinician-patient discussion. Patients cannot compare compounded retatrutide quality against an FDA-approved Lilly retatrutide product (which does not exist as of 2026-05-13) — they can only compare against research-grade reference material and other compounded retatrutide sources.

Pattern Z compliant patient-counseling beat for the compounded-retatrutide question:

“Compounded retatrutide as it exists in research-chemical and gray-market channels is a real phenomenon — patients seeking it typically have specific reasons (anticipated FDA approval, mechanism-class preference, prior within-class non-response). The operational landscape is structurally different from the compounded semaglutide / tirzepatide context that emerged during the 2022-2024 shortages, because there is no FDA-approved retatrutide for compounding pharmacies to compound from under shortage status. The sourcing is from research-chemical vendors and gray-market channels, and the quality variability is structurally greater than 503A/503B compounding. If you’re considering it, let’s review the specific sourcing vendor’s quality practices — certificate of analysis if available, vendor reputation, reconstitution and storage discipline — and walk through what we know and don’t know about the formulation. That’s how the decision gets made well in this pre-approval context.”

What Pattern Z compliance does NOT mean. It does not mean presenting compounded retatrutide as equivalent to investigational-supply retatrutide in every dimension; it does not mean presenting investigational supply as exclusively legitimate. It means presenting both as factual categories with their respective trade-offs, allowing the patient and clinician to make a choice anchored to the patient’s circumstances (access, mechanism-class preference, sourcing-vendor quality evaluation, regulatory-status comfort).

10.4 Pregnancy-planning conversation (Anchor 3 — LEADS with human research-state data)

For reproductive-age patients on anticipated retatrutide use (trial enrollment, investigational-supply off-label, or anticipated post-approval). The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or class-level contraindication framing — this lead-framing discipline is the core of canonical Anchor 3 (verbatim sema §6.8 calibration).

Required counseling beats:

• Human pregnancy-exposure data — Parker CH, Slattery C et al. Diabetes Obes Metab 2025 Aug PMID 40329607. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. Retatrutide-specific data within the pooled analysis is determined by the primary publication content; retatrutide trial-population unplanned-pregnancy exposure is structurally smaller than semaglutide / tirzepatide given the smaller exposed Phase 2/3 trial population.

• Pharmacokinetic facts (post-research-state-lead). Retatrutide half-life approximately 6 days; approximately 5 half-lives (approximately 30 days) for >95% pharmacokinetic clearance. With a conservative pharmacodynamic margin, approximately 60-day pre-conception discontinuation window.

• Standard practice framing. Discontinuation upon pregnancy awareness for retatrutide users (trial-enrollment patients: per trial-protocol discontinuation criteria; off-label investigational-supply patients: per clinician-judgment within informed-consent and class-level GLP-1 RA pregnancy contraindication framework).

• Animal data context. Class-level GLP-1 RA Category X-equivalent contraindication framing is class-level standard practice; animal data does not always translate to human teratogenicity profile; the Parker 2025 human pooled data shows reassuring early signal but is the load-bearing human evidence as of 2026-05-13.

• Post-discontinuation weight-regain trajectory. Class-level GLP-1 RA evidence base; retatrutide-specific evidence emerges from TRIUMPH-6 weight-maintenance Phase 3 trial.

• The patient’s reproductive-planning decision is patient-anchored. Some patients on protocol will plan conception within the next 1-2 years; some within the next decade; some are not planning conception at all but want awareness of the discontinuation arithmetic in case planning changes. The counseling beat presents the facts; the timing decision is patient-anchored.

• Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met and pending retatrutide regulatory status at the time of consideration.

Pattern Z anchor 3 compliance verification. This counseling beat LEADS with Parker 2025 human research-state data. PK facts, animal data + class-level Category X contraindication framing, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead, scoped as factual context. The patient’s decision is patient-anchored.

10.5 Comparator conversation (Anchor 4 — multi-dimensional fact presentation)

For patients with within-class alternative considerations (e.g., retatrutide vs tirzepatide vs semaglutide for CWM or T2D contexts). Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions — single-dimension comparison (weight magnitude alone) is the canonical pre-patch anti-anchor that steered patients away from acknowledging actual comparator advantages.

Pattern AA-precise comparator framing for retatrutide pre-approval state. Cross-trial comparison of an in-readout Phase 3 (retatrutide TRIUMPH program) vs a completed Phase 3 (semaglutide SELECT / STEP / ESSENCE / FLOW; tirzepatide SURMOUNT-1 / SURMOUNT-5) requires explicit Pattern AA caveats. The peer-reviewed cross-trial effect-size data, with epistemic-status framing per Pattern AA discipline:

Compound	Trial / readout	Effect	Dose / duration	Epistemic status
Retatrutide	Phase 2 obesity (Jastreboff 2023 NEJM PMID 37366315; NCT04881760; n=338)	−24.2%	12 mg / 48 weeks	peer-reviewed
Retatrutide	TRIUMPH-4 Phase 3 obesity + knee OA (NCT05931367; n=445)	−28.7%	12 mg / 68 weeks	sponsor disclosure Dec 11, 2025; peer-reviewed publication pending
Tirzepatide	SURMOUNT-1 Phase 3 obesity (Jastreboff 2022 NEJM)	−22.5%	15 mg / 72 weeks	peer-reviewed (Phase 3 completed)
Tirzepatide vs semaglutide head-to-head	SURMOUNT-5 Phase 3 (Aronne 2025 NEJM PMID 40353578; n=751)	tirzepatide −20.2% vs semaglutide −13.7%	week 72	peer-reviewed (Phase 3 completed)
Semaglutide	STEP-1 Phase 3 (Wilding 2021 NEJM)	−14.9%	2.4 mg / 68 weeks	peer-reviewed (Phase 3 completed)

Required multi-dimensional counseling beats:

• Weight-loss magnitude (Pattern V trial-anchored). Retatrutide Phase 2 obesity −24.2% at 12 mg / 48 weeks (peer-reviewed); retatrutide TRIUMPH-4 Phase 3 sponsor-disclosed −28.7% at 12 mg / 68 weeks (peer-reviewed primary publication pending). Tirzepatide SURMOUNT-1 −22.5% at 15 mg / 72 weeks; SURMOUNT-5 head-to-head −20.2% tirzepatide vs −13.7% semaglutide at 72 weeks; STEP-1 semaglutide −14.9% at 2.4 mg / 68 weeks. Cross-trial comparisons across separate trials with different protocols are research-state-indicative, not head-to-head. Head-to-head retatrutide vs tirzepatide data: TRIUMPH-5 (NCT06662383; n=800; primary completion 2026-12; ACTIVE_NOT_RECRUITING). Head-to-head retatrutide vs semaglutide T2D data: TRANSCEND-T2D-2 (NCT06260722; n=1,250; primary completion 2026-08; ACTIVE_NOT_RECRUITING).

• Regulatory status (Pattern AA precision). Semaglutide is FDA-approved (Wegovy CWM, Ozempic T2D + CV risk in T2D + non-diabetic-CVD per SELECT extension, FLOW CKD-in-T2D label expansion 2025, ESSENCE MASH F2/F3 label expansion 2025). Tirzepatide is FDA-approved (Mounjaro T2D, Zepbound CWM). Retatrutide is NOT FDA-approved as of 2026-05-13; Phase 3 readout-pending; FDA submission anticipated post-Phase 3 program completion per Eli Lilly investor communications; anticipated approval H1 2027 conditional on Phase 3 results and FDA review timelines.

• Cardiovascular outcomes evidence base. Semaglutide SELECT (PMID 37952131) demonstrated MACE composite HR 0.80 in obesity without diabetes (39.8 mo median follow-up; peer-reviewed Phase 3 completed). Tirzepatide SURMOUNT-MMO Phase 3 CV outcomes active. Retatrutide TRIUMPH-3 (severe obesity + CVD; primary completion 2026-04; ACTIVE_NOT_RECRUITING) + TRIUMPH-Outcomes (BMI ≥27 + ASCVD/CKD MACE/MAKE; n=10,000; primary completion 2029-02; ACTIVE_NOT_RECRUITING) — Phase 3 readout-pending.

• MASH approval status. Semaglutide FDA-approved for MASH F2/F3 per ESSENCE (PMID 40305708; Sanyal AJ, Newsome PN et al. NEJM 2025 Jun 5). Tirzepatide MASH program in development (SYNERGY-NASH Phase 2 PMID 38856224 — tirzepatide, NOT survodutide; SURMOUNT-MASH Phase 3 directional). Resmetirom (Madrigal) FDA-approved 2024 for non-cirrhotic F2/F3 MASH (non-GLP-1 mechanism class). Retatrutide MASH-indication Phase 2a substudy peer-reviewed (Sanyal 2024 PMID 38858523; −82.4% MRI-PDFF at 12 mg / 48 weeks; the largest MRI-PDFF reduction magnitude in any pharmacotherapy class as of 2026-05-13); Phase 3 MASH-indication characterization is research-state-pending via SYNERGY-Outcomes (NCT07165028).

• Kidney outcomes evidence base. Semaglutide FLOW (Perkovic V et al. NEJM 2024 PMID 38785209) demonstrated kidney composite + CV death HR 0.76 in T2D + CKD (peer-reviewed Phase 3 completed; FDA-approved indication 2025). Tirzepatide kidney outcomes in development. Retatrutide TRANSCEND-T2D-3 (T2D + renal impairment + basal insulin; n=320; primary completion 2026-10; ACTIVE_NOT_RECRUITING) + renal-outcomes Phase 2 (NCT05936151; n=146; COMPLETED 2025-10-01) — Phase 3 readout-pending.

• Ophthalmologic class-differentiation (NAION). Class-context differentiation per Lakhani M, Kwan ATH et al. Am J Ophthalmol 2025 Sep PMID 40383360: NAION signal documented for semaglutide; signal absent for tirzepatide at the same analytic threshold. Retatrutide-specific NAION-signal characterization is research-state-pending TRIUMPH Phase 3 ophthalmologic safety reporting. Pattern AA precision: this is a class-context post-marketing signal under research-state-active evaluation; not a labeled warning.

• Mechanism-class differentiation. Single GLP-1R (semaglutide) → dual GLP-1/GIP (tirzepatide) → triagonist GLP-1/GIP/glucagon (retatrutide). The GCGR-agonism component is mechanism-class-distinct (hepatic lipid oxidation, thermogenesis via futile substrate cycling); the Phase 2a MASLD substudy −82.4% MRI-PDFF reduction magnitude is mechanistically attributed primarily to the GCGR component. Patient with hepatic-IR-dominant phenotype or with MASLD context may have a mechanism-class preference toward retatrutide. Patient with prior tirzepatide intolerance (GIPR-component-related) may have a tolerability concern about retatrutide GIPR-agonism component shared with tirzepatide. Pattern V direction-of-effect: subgroup characterization research-state-pending Phase 3 data.

• GI tolerability profile. All three (semaglutide, tirzepatide, retatrutide) have GI-dominant AE profile; specific dose-by-dose tolerability differences emerge from primary publications. Retatrutide-specific tolerability characterization at the 12 mg dose from Phase 2 program.

• Route / platform availability. Semaglutide: SC injection (Wegovy/Ozempic) + oral (Rybelsus); tirzepatide: SC injection (Zepbound/Mounjaro) only as of 2026-05-13; retatrutide: SC investigational supply only (no commercial Lilly retatrutide product exists pre-approval).

• Cost and access. Patient-specific; insurance-coverage realities for FDA-approved compounds are class-context (semaglutide and tirzepatide vary by indication and jurisdiction); retatrutide access pre-approval is via trial enrollment, clinician-judgment off-label investigational-supply pathways, or gray-market / research-chemical-vendor compounded sources (per §10.3 framing).

Patient-counseling beat (verbatim canonical Anchor 4 framing — affirms both compounds; acknowledges advantages explicitly; closes with shared-decision-making):

“Semaglutide, tirzepatide, and retatrutide are all evidence-based weight-management options at different stages of development and approval. Semaglutide and tirzepatide are FDA-approved with established CV outcomes (semaglutide), MASH approval (semaglutide), CKD outcomes (semaglutide), and weight-loss-magnitude evidence base (both, with tirzepatide showing ~6.5 percentage points more weight loss than semaglutide at max-tolerated doses head-to-head in SURMOUNT-5). Retatrutide is in Phase 3 with the largest pre-Phase-3 weight-loss-magnitude data in the field (Phase 2 −24.2% at 12 mg / 48 weeks; TRIUMPH-4 Phase 3 sponsor-disclosed topline −28.7% at 12 mg / 68 weeks; peer-reviewed Phase 3 publication pending) and with the largest MASLD MRI-PDFF reduction magnitude in any pharmacotherapy class (Phase 2a substudy −82.4% at 12 mg / 48 weeks). The compounds differ on FDA approval status, on completed-vs-in-readout Phase 3 evidence-base maturity, on cardiovascular / kidney / MASH outcomes evidence base, on NAION class-differentiation, on triple-vs-dual-vs-single receptor mechanism, on GI tolerability profiles, on access pathways and cost. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.”

Pattern AA caveat verbatim for cross-trial framing (essential for retatrutide):

“Cross-trial comparison of an in-readout Phase 3 program (TRIUMPH for retatrutide) against completed Phase 3 programs (SURMOUNT for tirzepatide; STEP / SELECT / FLOW / ESSENCE for semaglutide) is research-state-indicative, not head-to-head. The TRIUMPH-4 −28.7% topline is sponsor-disclosed pending peer-reviewed publication; the Phase 2 −24.2% is the peer-reviewed retatrutide effect-size anchor. Head-to-head retatrutide vs tirzepatide data emerges from TRIUMPH-5 (primary completion 2026-12); head-to-head retatrutide vs semaglutide T2D data emerges from TRANSCEND-T2D-2 (primary completion 2026-08).”

10.6 Off-label / extrapolation conversation (Anchor 5 — DOMINANT subsection for retatrutide pre-approval state)

This is the dominant Pattern Z calibration subsection for retatrutide as of 2026-05-13. Because retatrutide has no FDA approval, every clinical use of retatrutide today is some form of (a) trial-enrollment under TRIUMPH program protocol, (b) clinician-judgment off-label use of investigational supply where research-protocol acquisition pathway exists, or (c) gray-market / research-chemical-vendor compounded use. The Anchor 5 framing — present trial-population scope as fact; frame extrapolation as research-state-incompleteness, not as “no” answer; explicit off-label labeling; informed-consent acknowledgement; close with shared-decision-making — is the dominant calibration surface.

Required counseling beats for retatrutide off-label / extrapolation conversation:

(a) Trial-enrollment pathway counseling. The TRIUMPH program comprises ten currently-registered Phase 3 trials (TRIUMPH-1 through TRIUMPH-9 plus TRIUMPH-Outcomes) plus three TRANSCEND-T2D registration trials plus SYNERGY-Outcomes Phase 3 multi-agent MASLD master protocol. As of 2026-05-13, RECRUITING trials open to new enrollment: TRIUMPH-7 (obesity + chronic low back pain), TRIUMPH-9 (obesity / overweight without T2D extended), SYNERGY-Outcomes (MASLD). Other TRIUMPH and TRANSCEND-T2D trials are ACTIVE_NOT_RECRUITING (closed to new enrollment but ongoing for already-enrolled participants). Trial-enrollment provides retatrutide access under trial-protocol provision, with retatrutide investigational supply provided by Eli Lilly, with trial-protocol-defined monitoring and follow-up. Patient eligibility for active trials depends on enrollment criteria match and site availability.

(b) Off-label use of investigational supply (where research-protocol acquisition pathway exists). Patient understands: retatrutide is not FDA-approved; clinical use is off-label; the trial-population evidence base supports the trial-protocol-defined dose ranges (Phase 2 obesity 12 mg / 48 weeks; TRIUMPH-4 Phase 3 12 mg / 68 weeks); microdosing or off-label extrapolation beyond trial-protocol dose ranges is research-state-novel without corresponding clinical-trial evidence. Informed-consent acknowledgement that the use is off-label and pre-approval; informed-consent acknowledgement that the safety and efficacy profiles will be characterized by Phase 3 readouts, with current characterization based on Phase 2 evidence base plus the TRIUMPH-4 sponsor-disclosed topline. Clinician-judgment within informed-consent standards and primary-source-supported clinical reasoning.

(c) Compounded retatrutide from research-chemical / gray-market sources (per §10.3 framing). Patient understands: compounded retatrutide operates outside the post-FDA-approval shortage-driven 503A/503B framework; sourcing-channel quality variability is structurally greater than 503A/503B compounding; no FDA-approved Lilly retatrutide reference standard exists for quality comparison. Clinician evaluates sourcing-vendor quality criteria (vendor reputation, certificate of analysis if available, reconstitution and storage discipline) within the pre-FDA-approval-compounding structural variability framework. Informed-consent acknowledgement at the sourcing-channel-quality layer in addition to the off-label-use layer.

(d) Microdosing / off-label-dose-range extrapolation. Pattern Z anchor 5 framing: the Phase 2/3 trial-population evidence base supports the trial-protocol-defined dose ranges (titrated to 8-12 mg as the most-effective Phase 2 obesity maintenance doses; the 12 mg dose is the highest-effect Phase 2 / TRIUMPH-4 dose). Microdosing for longevity / metabolic-health / cardiovascular-prevention use outside the trial-enrolled phenotype is research-state-novel — the effects at sub-trial doses are research-state-uncharacterized. The known AE profile (GI dominant per §6.2; gallbladder per §6.3; pancreatitis class-level per §6.4; NAION class-context per §6.5; cardiovascular class-level per §6.6; pregnancy class-level per §6.9; GCGR-component hepatic / cardiac / lean-mass per §6.10) applies whether the patient is in the studied population or not. Whether the cardiovascular / metabolic / hepatic benefit extrapolates beyond the trial-population is research-state-incomplete pending Phase 3 readouts.

(e) Extrapolation beyond trial-enrolled phenotype (e.g., retatrutide use in a lean / metabolically-healthy population not enrolled in any TRIUMPH trial; retatrutide use in pediatric / adolescent population not enrolled in any retatrutide Phase 3 trial; retatrutide use in pregnancy / lactation contexts class-level contraindicated). Pattern Z anchor 5 framing applies: trial-population scope as fact; extrapolation as research-state-incompleteness; informed-consent acknowledgement; shared-decision-making.

Patient-counseling beat (verbatim canonical Anchor 5 framing — adapted for retatrutide pre-approval state):

“Retatrutide is in Phase 3 development under the TRIUMPH program; it is not FDA-approved as of 2026-05-13. The current access pathways are: trial enrollment if you qualify and a site is available; clinician-judgment off-label use of investigational supply where research-protocol acquisition pathways exist; or compounded retatrutide from research-chemical / gray-market sources with the pre-FDA-approval-compounding structural variability we discussed in §10.3. The trial-population evidence base supports the dose ranges used in the Phase 2 program (titrated to 12 mg) and in TRIUMPH-4 Phase 3 (12 mg). Use outside the trial-population — different dose ranges, different phenotype, different indication — is research-state-incomplete; we don’t have Phase 3 evidence for those uses. The known side-effect profile is GI dominant, with class-level gallbladder, pancreatitis, NAION, and CV considerations, and with retatrutide-specific GCGR-component hepatic-biology and cardiac and lean-mass surveillance considerations. Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, what monitoring would matter if you decided to proceed, and which access pathway is workable for your circumstances.”

10.7 Discontinuation conversation (§8 anchor)

For patient-preference, indication-resolution, AE-driven, pre-conception, or trial-enrollment-completion discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override); indication-resolution (rare; framing is celebratory and prepares for re-initiation if regain); AE-attribution (clinical decision; per §6 AE-class framework); pre-conception planning (per §8.4 arithmetic; Pattern Z anchor 3 framing per §10.4); trial-enrollment-completion (per §8.7 Scenario E for pre-approval state operational considerations).
• Taper schedule (per §8.3): 12 mg → 8 mg × 4 weeks → 4 mg × 4 weeks → 2 mg × 4 weeks → off. Anticipated framework; patient-judgment within taper if accelerated discontinuation preferred. Pattern AA precision: anticipated framework; label-recommended specifics emerge from FDA approval.
• Post-discontinuation weight-regain framing (per §8.5): class-level GLP-1 RA trajectory data; retatrutide-specific evidence base via TRIUMPH-6 weight-maintenance Phase 3 (NCT06859268; primary completion 2028-04). Not pathologized; framed as expected biological response.
• Re-initiation pathway (per §8.6): available if regain occurs and warrants re-treatment; titration restarts at §4 starting dose (2 mg), not at prior maintenance dose; pending retatrutide regulatory status at the time of consideration.

10.8 Pattern Z self-audit on Section 10 counseling beats

The five Anchors + retatrutide-specific calibration are the self-audit checklist for this protocol’s §10 counseling-beat language. A Pattern Z violation in retatrutide-protocol §10 is positive if any of the following appear:

• Compounded retatrutide framed as default-suspect or as steered-against (e.g., “Compounded retatrutide should not be used because it is not FDA-approved” — violates the §10.3 retatrutide-specific calibration of Anchors 1+2; leads with what compounded retatrutide is not, rather than with what it IS in the pre-approval landscape).
• Pregnancy-planning framed with PK arithmetic LEADING and human research-state data SECONDARY (violates Anchor 3 LEAD discipline).
• Comparator framing using “most potent,” “best in class,” “next generation,” “leading,” “first-in-class triple agonist” (violates Pattern AA precision; the canonical body text explicitly excludes this vocabulary).
• Off-label use framed as if labeled (e.g., “Retatrutide is used for obesity” without “Retatrutide is in Phase 3 development for obesity; not FDA-approved as of 2026-05-13; current use is via trial enrollment or off-label investigational-supply” — violates Anchor 5 explicit-off-label-framing discipline).
• Single-dimension comparator framing (e.g., “Retatrutide is the most effective” — violates Anchor 4 multi-dimensional discipline).
• Single-mechanism-direction extrapolation framing (e.g., “Retatrutide will work better than tirzepatide because triagonist > dual incretin” — extrapolates mechanism-class differentiation beyond research-state evidence; violates Pattern V direction-of-effect).
• Investigational-supply / sourcing-channel framing without explicit informed-consent acknowledgement of the off-label use and the structural quality variability framework (violates §10.3 + §10.6 Pattern Z calibration).

The Section 10 production agent runs the seven-violation self-audit before handoff to the verification cycle.

---

11. Source citations

11.1 Purpose

Define the bibliography, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor identifier-integrity discipline for the retatrutide protocol. Every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor in this protocol traces to a §11 citation entry. Pattern AB.1 / AB.2 / AB.4 standing scans operate at this section.

11.2 Evidence hierarchy tiers (retatrutide-specific, with pre-FDA-approval state framing)

Pattern AA discipline applied to the evidence hierarchy: tiers for retatrutide reflect the pre-FDA-approval evidence-base state.

• Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. For retatrutide as of 2026-05-13, no Tier 1 retatrutide peer-reviewed Phase 3 publication exists. TRIUMPH-4 sponsor-disclosed Phase 3 topline (Eli Lilly press release December 11, 2025; −28.7% body weight reduction at 12 mg vs placebo at 68 weeks; NCT05931367) is anchored to NCT identifier and to the sponsor disclosure per Pattern AA-precise sponsor-disclosure-pending-peer-reviewed-publication framing. Peer-reviewed primary publication PMID assignment is pending as of 2026-05-13.
• Tier 1.5 — Phase 3 head-to-head RCT comparing within-class alternatives. For retatrutide: TRIUMPH-5 (retatrutide vs tirzepatide; NCT06662383; primary completion 2026-12; ACTIVE_NOT_RECRUITING) and TRANSCEND-T2D-2 (retatrutide vs semaglutide T2D; NCT06260722; primary completion 2026-08; ACTIVE_NOT_RECRUITING) are Phase 3 head-to-head designs — Phase 3 readout-pending.
• Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. For retatrutide: Jastreboff 2023 NEJM Phase 2 obesity (PMID 37366315), Rosenstock 2023 Lancet Phase 2 T2D (PMID 37385280), Sanyal 2024 Nat Med Phase 2a MASLD substudy (PMID 38858523), Urva 2022 Lancet Phase 1b MAD (PMID 36354040), Coskun 2022 Cell Metab discovery + clinical proof of concept (PMID 35985340). These are the retatrutide-specific peer-reviewed primary-publication evidence base anchors.
• Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. For retatrutide pre-approval: no retatrutide-specific post-marketing pharmacovigilance evidence exists. Class-level Tier 3 evidence (e.g., Lakhani 2025 NAION class-context PMID 40383360; Wen 2025 pancreatitis + pancreatic cancer SR + meta-analysis PMID 40988099; Ko 2026 cancer-context SR + meta-analysis PMID 41359966; Bjerre Knudsen 2010 rodent C-cell foundational paper PMID 20203154; Silverii 2024 thyroid cancer SR + meta-analysis PMID 38018310; Parker 2025 pooled regulatory pregnancy-exposure data PMID 40329607) is applied at the class level with retatrutide-specific Phase 3 readout-pending characterization.

11.3 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Pattern AB requires every PMID and NCT to be verified by content, not by existence. The protocol’s §11 carries the verified-identifier table. Verified against the Retatrutide canonical v1.0-final §11 Primary-source citation appendix.

The TRIUMPH-1 NCT discipline (canonical Phase 4 AB.2 hygiene application). TRIUMPH-1 NCT is NCT05929066 (NOT NCT05608252, which is an unrelated Dana-Farber Cancer Institute breast cancer trial — VS-6766 + abemaciclib + fulvestrant in HR+/HER2- metastatic breast cancer; sponsor Adrienne G. Waks). This protocol’s body text uses NCT05929066 consistently at every TRIUMPH-1 reference; Pattern AB.4 cascade scan verified.

The Lancet 2023 Aug incretin cluster discipline (canonical Phase 4 AB.1 hygiene application). PMID 37385280 is the retatrutide Phase 2 T2D paper (Rosenstock J, Frias J et al. Lancet 2023 Aug 12). PMID 37385275 is the tirzepatide SURMOUNT-2 paper (Garvey WT et al.) — DIFFERENT trial, different compound class. PMIDs 37385278 and 37385279 are oral semaglutide PIONEER PLUS. All four share epub date 2023-06-26 and arithmetically adjacent PMIDs; inversion-prevention discipline applied. This protocol’s body text cites PMID 37385280 as retatrutide Phase 2 T2D consistently.

The Coskun 2022 journal discipline (canonical Phase 4 AB.4 hygiene application). PMID 35985340 is the Coskun T, Urva S et al. Cell Metab 2022 Sep 6 discovery and clinical proof of concept paper — NOT J Clin Invest (some secondary literature has reported the incorrect journal). This protocol’s body text cites Cell Metab consistently.

The Giblin 2026 publication-type discipline (canonical Phase 4 AB.4 hygiene application). PMID 41090431 is the Giblin K, Kaplan LM et al. Diabetes Obes Metab 2026 Jan — TRIUMPH-1 and TRIUMPH-4 rationale and design publication. Pub-type is Journal Article only (no Clinical Trial / Phase indexing); this is a design paper, NOT a primary-results publication. This protocol’s body text frames PMID 41090431 as design-paper at every citation.

The Loomba 2024 / Sanyal 2024 same-NEJM-day discipline (canonical Phase 4 AB.1 hygiene application). PMID 38856224 is Loomba R, Hartman ML et al. NEJM 2024 Jul 25 — tirzepatide SYNERGY-NASH Phase 2 MASH (62% MASH resolution at 15 mg vs 10% placebo). PMID 38847460 is Sanyal AJ, Bedossa P et al. NEJM 2024 Jul 25 — survodutide Phase 2 MASH (62% MASH resolution at 6.0 mg vs 14% placebo). Same-NEJM-day same-effect-magnitude DIFFERENT compounds — inversion-prevention discipline. This protocol’s §7.4 / §10.5 MASH comparator framing applies the discipline.

11.4 Retatrutide-specific primary-source citations (Tier 2 — peer-reviewed Phase 1/2 + Phase 2a)

Mechanism and Phase 1 / 2.

• PMID 35985340 — Coskun T, Urva S et al. Cell Metabolism 2022 Sep 6 Vol 34 Iss 9 — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Mechanism characterization (GIPR EC50 ~0.06 nM; GLP-1R ~0.8 nM; GCGR ~5.8 nM) and clinical proof of concept in obesity and T2D. Cited in §1.1, §1.2, §1.3, §4.4, §6.10, §10.5. Pub-type Journal Article (mechanism paper; NOT a Phase-N RCT). Journal correction: Cell Metab NOT J Clin Invest. PubMed

• PMID 36354040 — Urva S, Coskun T et al. Lancet 2022 Nov 26 — LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled randomised trial. Phase 1b MAD; ~6-day elimination half-life supporting once-weekly dosing. Cited in §1.3, §8.4. Pub-type Randomized Controlled Trial | Multicenter Study | Clinical Trial Phase I | Journal Article. PubMed

• PMID 37366315 — Jastreboff AM, Kaplan LM et al. NEJM 2023 Aug 10 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NCT04881760; Phase 2 RCT n=338, 48 weeks. Up to −24.2% body weight reduction at 12 mg under treatment-policy estimand; 100% of 12 mg arm achieved ≥5% body weight reduction; 83% achieved ≥15%. Cited in §1.2, §4.3, §4.6, §5.2, §6.2, §7.4, §10.2, §10.5. Pub-type Randomized Controlled Trial | Clinical Trial Phase II | Journal Article. PubMed

• PMID 37385280 — Rosenstock J, Frias J et al. Lancet 2023 Aug 12 — retatrutide Phase 2 T2D paper (NOT SURMOUNT-2 tirzepatide which is PMID 37385275). NCT04867785; Phase 2 RCT n=281, 36 weeks; HbA1c and body-weight reductions across dose arms vs placebo and active-comparator dulaglutide 1.5 mg. Cited in §1.2, §4.3, §6.2, §10.2. Pub-type Randomized Controlled Trial | Clinical Trial Phase II | Journal Article. Pattern AB.1 inversion-prevention applied. PubMed

• PMID 38858523 — Sanyal AJ, Kaplan LM et al. Nat Med 2024 Jul — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. NCT04881760 (n=98 MASLD substudy of the Phase 2 obesity trial); up to −82.4% relative reduction in MRI-PDFF liver fat content at 48 weeks at 12 mg; 86% achieving normal liver fat <5%; dose-responsive HOMA2-IR + K-18 + pro-C3 reductions. Cited in §1.2, §3.4, §4.3, §5.2, §6.10, §6.12. Pub-type Journal Article | Randomized Controlled Trial | Clinical Trial Phase II. Pattern AB.4 framing: this is a Phase 2a substudy, NOT a Phase 3 trial. PubMed

TRIUMPH program design publication.

• PMID 41090431 — Giblin K, Kaplan LM et al. Diabetes Obes Metab 2026 Jan — Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH-1 and TRIUMPH-4 trials. Design paper for TRIUMPH-1 + TRIUMPH-4 (per the trial titles). Pub-type Journal Article only — no Clinical Trial / Phase indexing — Pattern AB.4 framing discipline: design paper, NOT primary-results publication. Cited in §1.2, §3.7, §4.2, §4.3, §5.2, §6.11. PubMed

TRIUMPH-4 Phase 3 sponsor disclosure (peer-reviewed publication pending).

• NCT05931367 — TRIUMPH-4 — Phase 3 obesity / overweight + knee osteoarthritis; n=445; 68 weeks; COMPLETED 2025-11-14. Eli Lilly investor communication December 11, 2025: −28.7% body weight reduction at 12 mg vs placebo. Peer-reviewed primary publication PMID assignment pending as of 2026-05-13. Cited in §1.1, §1.2, §4.3, §4.6, §5.2, §7.4, §10.5. Pattern AA-precise sponsor-disclosure-pending-peer-reviewed-publication framing applied at every citation.

TRIUMPH program Phase 3 trials (per ClinicalTrials.gov v2 API verification per Retatrutide canonical v1.0-final §3.3 verified trial roster).

• NCT05929066 — TRIUMPH-1 (n=2,300; primary completion 2026-04; ACTIVE_NOT_RECRUITING) — master-protocol obesity / overweight without T2D covering knee OA and OSA subgroups. NOT NCT05608252 which is unrelated Dana-Farber Cancer Institute breast cancer trial. Pattern AB.2 cascade discipline applied.
• NCT05929079 — TRIUMPH-2 (n=1,000; primary completion 2026-05; ACTIVE_NOT_RECRUITING) — Phase 3 obesity + T2D.
• NCT05882045 — TRIUMPH-3 (n=1,800; primary completion 2026-04; ACTIVE_NOT_RECRUITING) — Phase 3 severe obesity + established cardiovascular disease.
• NCT06662383 — TRIUMPH-5 (n=800; primary completion 2026-12; ACTIVE_NOT_RECRUITING) — head-to-head vs tirzepatide.
• NCT06859268 — TRIUMPH-6 (n=643; primary completion 2028-04; ACTIVE_NOT_RECRUITING) — weight reduction maintenance.
• NCT07035093 — TRIUMPH-7 (n=586; primary completion 2027-09; RECRUITING) — obesity + chronic low back pain.
• NCT07232719 — TRIUMPH-8 (n=250; primary completion 2027-07; ACTIVE_NOT_RECRUITING) — obesity (subpopulation).
• NCT07357415 — TRIUMPH-9 (n=600; primary completion 2028-10; RECRUITING) — obesity / overweight without T2D extended.
• NCT06383390 — TRIUMPH-Outcomes (n=10,000; primary completion 2029-02; ACTIVE_NOT_RECRUITING) — BMI ≥27 + ASCVD/CKD event-driven MACE/MAKE composite.

TRANSCEND-T2D Phase 3 trials.

• NCT06354660 — TRANSCEND-T2D-1 (n=537; COMPLETED 2026-01-22) — T2D + diet and exercise.
• NCT06260722 — TRANSCEND-T2D-2 (n=1,250; primary completion 2026-08; ACTIVE_NOT_RECRUITING) — T2D vs semaglutide active comparator.
• NCT06297603 — TRANSCEND-T2D-3 (n=320; primary completion 2026-10; ACTIVE_NOT_RECRUITING) — T2D + moderate-severe renal impairment + basal insulin.

SYNERGY-Outcomes MASLD master protocol.

• NCT07165028 — Phase 3 multi-agent including retatrutide (n=4,500; primary completion 2030-08; RECRUITING) — MASLD master protocol.

Retatrutide-specific Phase 1 / Phase 2 supporting trials.

• NCT05445232 — Phase 1 DDI study in obese participants (n=32; COMPLETED 2023-02-24).
• NCT06808802 — Phase 1 metoprolol PK DDI in healthy participants (n=30; COMPLETED 2025-04-15).
• NCT05916560 — Phase 1 hepatic impairment population pharmacokinetics (n=43; COMPLETED 2025-03-02).
• NCT05611957 — Phase 1 renal impairment population pharmacokinetics (n=29; COMPLETED 2023-09-05).
• NCT06313528 — Phase 1 calorie consumption (n=85; COMPLETED 2025-08-26).
• NCT06982846 — Phase 1 hypoglycemia counter-regulatory response in T2D (n=78; ACTIVE_NOT_RECRUITING).
• NCT06982859 — Phase 1 insulin secretion + sensitivity in T2D (n=95; RECRUITING).
• NCT06039826 — Phase 1 postmenopausal female overweight / obese (n=46; COMPLETED 2024-07-11).
• NCT05959096 — Phase 1 high-BMI healthy (n=85; COMPLETED 2024-07-25).
• NCT06003465 — Phase 1 injection device formulation similarity (n=57; COMPLETED 2024-02-08).
• NCT04823208 — Phase 1 Japanese T2D (n=64; COMPLETED 2022-06-23).
• NCT05548231 — Phase 1 Chinese obesity / overweight (n=32; COMPLETED 2023-07-27).
• NCT05936151 — Phase 2 effect of retatrutide on renal function in overweight / obesity + CKD with or without T2D (n=146; COMPLETED 2025-10-01).

11.5 Class-level cancer-context safety + pharmacovigilance citations (Tier 3 class-level)

• PMID 41359966 — Ko A, Chang YC et al. Ann Intern Med 2026 Feb — Risk for Cancer With GLP-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Class-level SR + meta-analysis 11 cancers + 2 conditions across certainty tiers. Cited in §6.11, canonical §5.0/§5.4/§5.5. PubMed
• PMID 40988099 — Wen J, Nadora D et al. Endocrinol Diabetes Metab 2025 Sep — Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Class-level SR + meta-analysis. Cited in §2.4, §6.4, canonical §5.3/§6.4. PubMed
• PMID 40383360 — Lakhani M, Kwan ATH et al. Am J Ophthalmol 2025 Sep — Association of GLP-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Multicenter Observational Pharmacovigilance Study. NAION class-differentiation finding (signal documented for semaglutide; absent for tirzepatide). Cited in §3.7, §6.5, §6.12, §10.5. Pub-type Multicenter Observational Pharmacovigilance Study, NOT SR/MA per Phase 4 AB.4 hygiene. PubMed
• PMID 40329607 — Parker CH, Slattery C et al. Diabetes Obes Metab 2025 Aug — GLP-1 receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials. Pooled regulatory pregnancy-exposure data, NOT SR per Phase 4 AB.4 hygiene. Cited in §6.9, §8.7, §10.4. Pattern Z anchor 3 LEADING source. PubMed
• PMID 20203154 — Bjerre Knudsen L, Madsen LW et al. Endocrinology 2010 Apr — GLP-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Foundational rodent C-cell mechanism paper. Cited in §2.4, §3.7, §6.11. PubMed
• PMID 38018310 — Silverii GA, Monami M et al. Diabetes Obes Metab 2024 Mar — GLP-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of RCTs. Class-level thyroid cancer SR + meta-analysis. PubMed

11.6 Comparator-class citations (Tier 1 / Tier 1.5 — FDA-approved class context)

• PMID 37952131 — Lincoff AM, Brown-Frandsen K et al. NEJM 2023 Dec 14 — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Three-point MACE HR 0.80 in obesity without diabetes at 39.8 mo median follow-up. NCT03574597. Cited in §1.2, §6.6, §10.5. PubMed
• PMID 40353578 — Aronne LJ, Horn DB et al. NEJM 2025 Jul 3 — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 head-to-head). Tirzepatide −20.2% vs semaglutide −13.7% at week 72; n=751. Cited in §7.5, §9.5, §10.5. PubMed
• PMID 40305708 — Sanyal AJ, Newsome PN et al. NEJM 2025 Jun 5 — Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). FDA-approved indication-establishing for semaglutide in non-cirrhotic F2/F3 MASH. NCT04822181. Cited in §1.2, §4.3, §7.4, §10.5. PubMed
• PMID 38856224 — Loomba R, Hartman ML et al. NEJM 2024 Jul 25 — Tirzepatide for MASH with Liver Fibrosis (SYNERGY-NASH Phase 2). 62% MASH resolution at 15 mg vs 10% placebo. Tirzepatide, NOT survodutide. Pattern AB.1 inversion-prevention discipline. PubMed
• PMID 38847460 — Sanyal AJ, Bedossa P et al. NEJM 2024 Jul 25 — A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. 62% MASH resolution at 6.0 mg vs 14% placebo. Survodutide, NOT tirzepatide. Pattern AB.1 inversion-prevention discipline. PubMed
• PMID 38785209 — Perkovic V et al. NEJM 2024 — Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). Kidney composite + CV death HR 0.76 at median 3.4 years; FDA-approved indication 2025. NCT03819153. Cited in §7.4, §10.5. PubMed

11.7 Retatrutide-specific triagonist mechanism + preclinical citations (Tier 2 — mechanism)

• PMID 40613938 — Naunyn Schmiedebergs Arch Pharmacol 2026 Jan — Inotropic effects of retatrutide in isolated human atrial preparations. Cardiac glucagon-receptor inotropic-effects characterization at GCGR-active concentrations. Cited in §3.6, §6.6, §6.10, canonical §2.3/§6.6/§6.13. PubMed
• PMID 41582189 — Eur J Med Res 2026 Jan 26 — Effect of GLP-1 RA on heart rate in non-diabetic individuals (class-level data including retatrutide). Cited in §3.6, §5.3, §6.6. PubMed
• PMID 41478576 — Pharmacol Res 2026 Jan — IUPHAR review on glucagon receptor pharmacology. GCGR biased-agonism research-state context. PubMed
• PMID 41997446 — Mol Metab 2026 Apr — GIPR:GCGR co-agonism restores normal weight in obese rodents. Preclinical mechanism paper. PubMed
• PMID 41964043 — Diabetol Metab Syndr 2026 Apr 10 — Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming. Preclinical mechanism paper. PubMed
• PMID 41741376 — Obesity (Silver Spring) 2026 Feb — Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Preclinical MASH-model paper. PubMed

11.8 Cross-references and cross-canonical anchors

• /obsidian-peptides/Peptides/Retatrutide.md v1.0-final (2026-05-12) — canonical reference document; this protocol traces every effect-size and dose-threshold and AE-class claim to the canonical’s verified-source inventory.
• /obsidian-peptides/Methodology/Protocol Template.md post-patch 20e66bd — structural authority for the 12-section + appendices protocol architecture.
• /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — Pattern Z 5-anchor verbatim calibration baseline (semaglutide v1.0-final §8.3.2, §12.10 Pattern 2, §6.8, §12.10 Pattern 6, §12.10 Pattern 8).
• /obsidian-peptides/Peptides/Semaglutide.md — comparator-class canonical (single GLP-1R; FDA-approved Wegovy/Ozempic/Rybelsus; SELECT/STEP/SUSTAIN/ESSENCE/FLOW Phase 3 evidence base).
• /obsidian-peptides/Peptides/Tirzepatide.md — comparator-class canonical (dual GLP-1/GIP; FDA-approved Mounjaro/Zepbound; SURMOUNT/SURPASS Phase 3 evidence base).
• /obsidian-peptides/Peptides/Survodutide.md — comparator-class canonical (dual GLP-1/glucagon; pre-FDA-approval; SYNCHRONIZE-1 + LIVERAGE Phase 3 evidence base).
• /obsidian-peptides/Process/Retatrutide/ — production artifacts including Bibliography, Bibliography AB-hygiene, Verification-Agent-Review, Primary-Source-Verification-v1, Adversarial-Review-iteration1.

11.9 Pattern AB.4 standing-scan applied to §11

Every PMID and NCT in this §11 has been content-verified against the Retatrutide canonical v1.0-final §11 Primary-source citation appendix (which was itself verified at canonical PSV iteration 1 — 26/26 PMIDs + 16/16 NCTs + 11/11 effect-size claims + 26/26 author attributions + 10/10 regulatory-status claims verified CLEAN). The cascade-failure pattern (NCT05608252 misattribution as TRIUMPH-1) is prevented by the explicit NCT05929066 anchoring in §11.4 and at every protocol-body citation. The Pattern AB.1 / AB.2 / AB.4 standing-scan is verified complete.

---

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree for retatrutide that integrates §1–§11 into a single navigable clinical-education reference. Section 12 is the operational summary that a clinician reaches for at point-of-care to navigate the protocol decisions for retatrutide in the pre-FDA-approval state: should this patient be considered for trial enrollment, what indication anticipated post-approval applies, what is the starting and target dose, what is the monitoring cadence, what are the off-ramps.

Section 12 is rendered as an ASCII flowchart for the high-level decision branches plus a phenotype-guided decision matrix. The decision tree is not authority — it summarizes the authoritative content in §1–§11; if the decision tree and a §1–§11 sub-block disagree, the §1–§11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS — RETATRUTIDE CONSIDERATION
                                |
                                v
                  [§1] Indication scope (anticipated)
                  Phase 3 TRIUMPH program in active execution;
                  retatrutide NOT FDA-approved as of 2026-05-13.
                                |
                                v
                  [§2] Selection criteria
                  - Anticipated inclusion met?   --> NO  --> Out of protocol
                  - Relative exclusion?          --> Clinician judgment
                  - Hard contraindication?       --> YES --> Out of protocol
                  (MTC/MEN-2 class-level; severe prior pancreatitis;
                   pregnancy in CWM; hypersensitivity)
                                |
                                v (inclusion met; no contraindication)
                  [§3] Pre-treatment workup (seven panels)
                  - Standard metabolic + diabetes-specific (if T2D)
                  - MASH-specific (if MASLD/MASH or MASH risk profile)
                  - Kidney-specific (if CKD or borderline)
                  - CV-risk-specific (if CVOT-anticipated or ASCVD)
                  - Organ-baseline (thyroid, pancreas, ophthalmology)
                  - Body composition baseline (DEXA preferred per GCGR-component)
                                |
                                v
                  [Access pathway decision]
                  (a) TRIUMPH trial enrollment if eligible + site available;
                  (b) Clinician-judgment off-label investigational supply;
                  (c) Compounded retatrutide from research-chemical/gray-market
                      sources (per §10.3 framing; pre-FDA-approval-compounding
                      structural variability acknowledged);
                  (d) Wait for anticipated FDA approval (post-Phase 3) and
                      transition then.
                                |
                                v
                  [§4] Initiation (if (a) or (b) selected)
                  - Phase 2 obesity titration: 2mg → 4mg → 6-8mg → 9-12mg/12wk
                  - TRIUMPH Phase 3 anticipated: 2mg → 4mg → 8mg → 12mg/4wk steps
                  - GI tolerability management at each step
                  - Early monitoring at Week 2, 5-6, 9-12, 16-20
                                |
                                v (target dose attained)
                  [§5] Maintenance (anticipated 8 mg or 12 mg)
                  - Target dose quarterly Y1, biannual thereafter
                  - Retatrutide-specific: ALT/AST (GCGR-component);
                    body comp (lean-mass surveillance per GCGR-component);
                    heart rate + cardiac surveillance per PMID 40613938
                                |
                                v
                  [§6/§7/§8] Branch points
                  - AE emerges? --> §6 AE-class algorithm
                  - Plateau/non-response? --> §7 algorithm
                  - Discontinuation trigger? --> §8 taper + Pattern Z framing
                                |
                                v
                  [§9] Combination decisions
                  - Within-Module-5 (SGLT2, insulin, metformin)
                  - Cross-Module (M5.6 lean-mass stack particularly relevant
                    given GCGR-component lean-mass concern)
                  - Contraindicated combinations avoided (within-class
                    overlap with semaglutide/tirzepatide/survodutide/MariTide)
                                |
                                v
                  [§10] Counseling beats
                  - Pattern Z 5-anchor compliance at every conversation;
                  - §10.3 pre-FDA-approval compounded framing (not 503A/503B);
                  - §10.4 pregnancy LEADS with Parker 2025 human data;
                  - §10.5 multi-dimensional comparator with in-readout-vs-
                    completed Phase 3 caveat;
                  - §10.6 OFF-LABEL DOMINANT for retatrutide pre-approval.
                                |
                                v
                  [§11] All claims source-anchored
                  - Tier 1/1.5/2/3 evidence hierarchy with pre-FDA-approval
                    state framing (Tier 1 retatrutide-specific is empty
                    pre-Phase-3-publication; TRIUMPH-4 sponsor disclosure
                    framed per Pattern AA precision)
                  - Pattern AB.4 identifier-integrity verified
                                |
                                v
                  [Appendix A] Verification gate

12.3 Phenotype-guided decision matrix

A markdown table mapping the §1.3 phenotype dimensions to the retatrutide consideration framework. The matrix is a clinical-education navigation aid for the pre-FDA-approval state, not a current-prescribing decision authority.

Phenotype dimension	Pattern	Retatrutide fit (anticipated post-approval)	Current access pathway (2026-05-13)	Comparator-class option (FDA-approved)
Indication = obesity, BMI ≥30, no T2D	Anticipated TRIUMPH-1/-9	Anticipated CWM scope; 12 mg target	TRIUMPH-9 RECRUITING; SYNERGY-Outcomes if MASLD	Wegovy 2.4 mg (STEP-1); Zepbound 15 mg (SURMOUNT-1); SURMOUNT-5 head-to-head
Indication = obesity + T2D	Anticipated TRIUMPH-2	Anticipated CWM + T2D scope; 12 mg	TRIUMPH-2 ACTIVE_NOT_RECRUITING; TRANSCEND-T2D-2 ACTIVE_NOT_RECRUITING	Ozempic 1.0-2.0 mg; Mounjaro / Zepbound 15 mg
Indication = T2D + diet/exercise	Anticipated TRANSCEND-T2D-1	Anticipated T2D scope	TRANSCEND-T2D-1 COMPLETED 2026-01; primary publication pending	Ozempic / Trulicity / Mounjaro per ADA/EASD
Indication = T2D + renal impairment + basal insulin	Anticipated TRANSCEND-T2D-3	Anticipated T2D + advanced-CKD scope	TRANSCEND-T2D-3 ACTIVE_NOT_RECRUITING	Ozempic FLOW PMID 38785209 FDA-approved 2025
Indication = severe obesity + established CVD	Anticipated TRIUMPH-3	Anticipated severe-obesity-CVD scope	TRIUMPH-3 ACTIVE_NOT_RECRUITING	Wegovy SELECT PMID 37952131; SURMOUNT-MMO active
Indication = BMI ≥27 + ASCVD/CKD (MACE/MAKE)	Anticipated TRIUMPH-Outcomes	Long-horizon event-driven CV/kidney	TRIUMPH-Outcomes ACTIVE_NOT_RECRUITING (n=10,000)	SELECT for sema; SURMOUNT-MMO for tirz
Indication = obesity + knee OA	Anticipated TRIUMPH-4	TRIUMPH-4 sponsor-disclosed -28.7% topline	TRIUMPH-4 COMPLETED 2025-11-14; peer-reviewed pending	No FDA-approved GLP-1 RA for knee OA indication as of 2026-05-13
Indication = MASLD / MASH	Phase 2a substudy + SYNERGY-Outcomes	Phase 2a −82.4% MRI-PDFF at 12 mg	SYNERGY-Outcomes RECRUITING (multi-agent)	Wegovy ESSENCE PMID 40305708 FDA-approved MASH F2/F3; resmetirom
Indication = weight maintenance after weight loss	Anticipated TRIUMPH-6	Long-horizon maintenance trajectory	TRIUMPH-6 ACTIVE_NOT_RECRUITING (n=643)	Wegovy continued; Zepbound continued
Indication = obesity + chronic low back pain	Anticipated TRIUMPH-7	Musculoskeletal-pain comorbidity scope	TRIUMPH-7 RECRUITING (n=586)	No FDA-approved GLP-1 RA for CLBP indication as of 2026-05-13
Phenotype: MTC / MEN-2 personal/family hx	Class-level hard contraindication	OUT OF PROTOCOL	OUT OF PROTOCOL	Non-GLP-1 alternative
Phenotype: severe prior pancreatitis	Class-level hard contraindication	OUT OF PROTOCOL	OUT OF PROTOCOL	Non-GLP-1 alternative
Phenotype: pregnancy / lactation	Class-level pregnancy contraindication	OUT OF PROTOCOL — immediate discontinuation if pregnancy on protocol	OUT OF PROTOCOL	Pre-pregnancy / post-pregnancy reinitiation per §8.6
Phenotype: pre-conception planning	Anchor 3 framing	~60-day washout per ~6-day half-life + margin	Trial-protocol contraception requirements	Same arithmetic for FDA-approved class
Phenotype: prior tirzepatide intolerance (GIPR-component-related)	Pattern V signal	Research-state-incomplete; 8 mg tolerability-preferred option vs 12 mg	TRIUMPH-5 head-to-head data pending (NCT06662383; 2026-12)	Semaglutide (no GIPR component); survodutide pre-approval
Phenotype: lean-mass concern (GCGR-component)	M5.6 stack consideration	Anticipated GCGR-component lean-mass-catabolism research direction	M5.6 v3 stack consideration per §9.3 + Anchor 5 framing	Tirzepatide lean-mass sub-analyses; resistance training co-prescription
Phenotype: cost / access barrier	Anchor 5 framing	Pre-FDA-approval state — investigational-supply vs gray-market	Trial enrollment if eligible; off-label investigational supply; compounded sourcing per §10.3	Compounded semaglutide / tirzepatide where 503A/503B framework applies
Phenotype: hepatic-IR-dominant + MASLD	Mechanism-class preference signal	Phase 2a MRI-PDFF magnitude is mechanism-class-distinct	SYNERGY-Outcomes RECRUITING; off-label investigational supply	Wegovy ESSENCE for MASH F2/F3

12.4 Worked example — decision-tree walkthrough for the §1.5 polycondition patient

The 54-year-old female with BMI 36, T2D HbA1c 8.4, ASCVD (prior MI 4 years ago), MASLD (FIB-4 2.1, FibroScan 9 kPa), eGFR 64, UACR 145, post-menopausal, prior tirzepatide intolerance, currently on metformin + dulaglutide.

Decision-tree walkthrough.

Step 1 — Indication scope (§1). Multiple anticipated retatrutide indications apply per the matrix: anticipated CWM + T2D (TRIUMPH-2 scope); anticipated severe-obesity-CVD (TRIUMPH-3 scope; her BMI 36 + ASCVD); anticipated BMI ≥27 + ASCVD/CKD (TRIUMPH-Outcomes scope; her ASCVD + CKD-borderline); anticipated MASLD (SYNERGY-Outcomes scope). Polycondition phenotype.

Step 2 — Selection criteria (§2). Inclusion criteria met for all four anticipated indications. No hard contraindications. Prior tirzepatide intolerance is a Pattern V signal (§2.5) — relative-exclusion-vs-clinician-judgment posture for the GIPR-component-tolerability research question.

Step 3 — Pre-treatment workup (§3). Full panel given polycondition: standard metabolic, diabetes-specific (HbA1c, C-peptide, dilated retinal exam at HbA1c 8.4), MASH-specific (FIB-4 2.1 known, FibroScan 9 kPa known, MRI-PDFF baseline, viral hepatitis screen, iron studies), kidney-specific (UACR 145 known, eGFR 64 known, RAS-blockade documentation), CV-risk-specific (ECG, troponin if symptomatic, echocardiogram if HFpEF-suspect), organ-baseline (TSH, lipase, ophthalmology with NAION-context awareness), body-composition DEXA.

Step 4 — Access pathway decision. As of 2026-05-13, her access options per the matrix:

• TRIUMPH-2 / -3 / -Outcomes ACTIVE_NOT_RECRUITING; she cannot enroll in these.
• TRANSCEND-T2D-2 / -3 ACTIVE_NOT_RECRUITING; she cannot enroll in these.
• TRIUMPH-7 RECRUITING if she has chronic low back pain (not stated in her case).
• TRIUMPH-9 RECRUITING (obesity / overweight without T2D extended) — her T2D may disqualify per the specific enrollment criteria; verify against ClinicalTrials.gov current criteria.
• SYNERGY-Outcomes RECRUITING (MASLD multi-agent) — candidate per her MASLD profile; pending site availability and enrollment eligibility.
• Clinician-judgment off-label use of investigational supply via research-protocol acquisition pathway — pending whether such pathway is available.
• Compounded retatrutide from research-chemical / gray-market sources — per §10.3 framing.
• Continue current regimen (dulaglutide + metformin) and prepare for anticipated retatrutide availability post-approval.

Step 5 — Initiation framework (§4). If she pursues access pathway (b), (c), or anticipated post-approval pathway: Phase 2 obesity titration framework (2 mg → 4 mg → 6-8 mg → 9-12 mg over ~12 weeks) or anticipated Phase 3 framework (2 mg → 4 mg → 8 mg → 12 mg with 4-week intervals). Given her tirzepatide intolerance signal, slow-titration option or 8 mg tolerability-preferred maintenance dose is the conservative starting framework.

Step 6 — Maintenance framework (§5). Anticipated target 8 mg (tolerability-preferred given the dual-incretin-intolerance signal) or 12 mg (highest-effect dose). Patient-clinician shared decision-making per Pattern Z. Quarterly Y1 monitoring with retatrutide-specific ALT/AST surveillance per GCGR-component framework, body-composition DEXA, heart rate + cardiac surveillance.

Step 7 — Branch points (§6/§7/§8). Anticipated AE profile per §6.2; GCGR-component-specific hepatic-biology / cardiac / lean-mass surveillance per §6.10; non-response algorithm per §7 if effect-size sub-trajectory; discontinuation framework per §8.

Step 8 — Combination decisions (§9). Concurrent dulaglutide discontinuation at retatrutide initiation (within-class mechanism-overlap contraindicated per §9.4). Concurrent metformin continued. Consider adding SGLT2 inhibitor (empagliflozin or dapagliflozin) for additive CV / kidney benefit (well-supported by individual-agent CVOT / KOOT data; mechanism-additive). Lean-mass stack (M5.6 v3 CJC-1295 / Ipamorelin) consideration if DEXA surveillance shows excess lean-mass loss.

Step 9 — Counseling beats (§10). Initiation conversation per §10.2 with explicit pre-FDA-approval framing and access-pathway shared decision-making. Compounded framing per §10.3 if she considers gray-market sourcing. Pregnancy-planning not applicable (post-menopausal). Comparator conversation per §10.5 with Pattern AA in-readout-vs-completed Phase 3 caveat (her current dulaglutide is FDA-approved peer-reviewed Phase 3; retatrutide is Phase 3 in-readout sponsor-disclosed). Off-label / extrapolation conversation per §10.6 dominant framing given the pre-FDA-approval state.

Step 10 — Source citations (§11). All claims traced: Phase 2 obesity Jastreboff 2023 PMID 37366315; Phase 2 T2D Rosenstock 2023 PMID 37385280; Phase 2a MASLD Sanyal 2024 PMID 38858523; TRIUMPH-4 sponsor disclosure NCT05931367 + Eli Lilly press release December 11, 2025; class-comparator citations.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with anticipated effect-size estimates and explicit pre-FDA-approval qualification at every step. The polycondition phenotype is anchored to multiple anticipated indication categories without inflating cross-indication benefit. The access-pathway decision is presented as factual options (trial enrollment, off-label investigational supply, compounded sourcing, continue-current-and-wait-for-approval), with the patient and clinician deciding which factors matter most. The comparator framing presents alternative-class options without steering. The off-label / extrapolation transparency is dominant given the pre-FDA-approval state. No “approved” / “FDA-approved” claim slipped through; every retatrutide regulatory framing carries the anticipated / Phase 3 readout-pending / pre-FDA-approval qualification.

---

Appendix A. Verification gate

A.1 Verification cycle reference

This protocol passes through the Module 5 four-step verification cycle per /Methodology/Protocol Template.md Appendix A: (1) Production-agent draft (this protocol); (2) Primary-Source-Verification-Agent iteration; (3) Independent-Adversarial-Reviewer-Agent iteration; (4) Dr. Gross verification gate.

The protocol’s verification chain is informed by the Retatrutide canonical v1.0-final verification chain (Phase 10 Dr. Gross simulation CLEAN; Phase 10.5 PSV iter 1 CLEAN 26/26 PMIDs + 16/16 NCTs verified; Phase 11 Independent Adversarial Reviewer iter 1 READY TO SHIP; Phase 12 v1.0-final committed). Protocol-specific verification re-runs the cycle against the protocol’s specific structural authority (Protocol Template post-patch 20e66bd).

A.2 Self-audit findings (production-agent step)

See Appendix C.

---

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2

• §1 opens with what retatrutide IS and the clinical-education framing; not with regulatory deficits.
• §2 ordering: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication.
• §6 opens with anticipatory framing per AE-class.
• §6.9 pregnancy LEADS with Parker 2025 human research-state data (Pattern Z anchor 3).
• §7 opens with diagnostic distinctions (pseudo-plateau vs true plateau vs non-response).
• §8 opens with discontinuation triggers framed as legitimate clinical pathway.

B.2 Pattern V

Every effect-size claim is anchored to its primary source with population qualification and epistemic-status framing: Phase 2 obesity −24.2% at 12 mg / 48 weeks (Jastreboff 2023 NCT04881760 peer-reviewed); TRIUMPH-4 −28.7% at 12 mg / 68 weeks (NCT05931367 sponsor-disclosed December 11, 2025; peer-reviewed publication pending); Phase 2a MASLD −82.4% MRI-PDFF at 12 mg / 48 weeks (Sanyal 2024 NCT04881760 substudy n=98 peer-reviewed). Cross-trial comparisons explicitly framed per Pattern AA in-readout-vs-completed Phase 3 caveat (§10.5).

B.3 Pattern W

Structural-count claims locked at §1.2 and reconciled end-to-end: ten TRIUMPH trials (TRIUMPH-1 through TRIUMPH-9 plus TRIUMPH-Outcomes) plus three TRANSCEND-T2D + SYNERGY-Outcomes. Reconciled at §3.7, §4.2, §5.2, §7.4, §9.2, §10.5, §11.4, §12.3.

B.4 Pattern Z 5-anchor calibration

• Anchor 1 (compounded operational characteristics). Retatrutide-specific calibration at §10.3 — pre-FDA-approval compounded framing operates outside the post-FDA-approval 503A/503B framework; LEADS with what compounded retatrutide IS in the pre-approval landscape.
• Anchor 2 (compounded vs FDA-approved counseling beat). Retatrutide-specific calibration at §10.3 — essentially N/A pre-approval; reframed as investigational-supply-acquisition framing vs gray-market / research-chemical-vendor framing.
• Anchor 3 (pregnancy section research-state-leading structure). Applied at §6.9 and §10.4 — LEADS with Parker 2025 PMID 40329607 human research-state data; PK arithmetic and class-level Category-X-equivalent framing appear AFTER the research-state lead.
• Anchor 4 (multi-dimensional comparator framing). Applied at §10.5 — 9-dimension fact presentation; affirms all compounds; closes with shared-decision-making invitation; Pattern AA in-readout-vs-completed Phase 3 caveat verbatim.
• Anchor 5 (off-label / extrapolation transparency). DOMINANT subsection at §10.6 for retatrutide pre-approval state; trial-enrollment + off-label investigational-supply + compounded sourcing + microdosing extrapolation + phenotype extrapolation all framed per Anchor 5 discipline.

B.5 Pattern AA — regulatory-claim precision (CRITICAL for retatrutide pre-approval state)

Every regulatory claim carries the pre-approval qualification. Body-text vocabulary excluded: “approved” / “FDA-approved” (except in the negative “not yet approved” or when referring to FDA-approved class comparators); “first-in-class” / “best-in-class” / “next-generation” / “leading-class” / “most potent” / “emerging” / “promising.” Body-text vocabulary defaults: “investigational,” “Phase 3 readout pending,” “anticipated FDA submission post-Phase 3 program completion,” “anticipated approval H1 2027 conditional on Phase 3 results and FDA review timelines,” “sponsor-disclosure-pending-peer-reviewed-publication” (for TRIUMPH-4 topline), “research-state-pending” (for Phase 3 readout-pending characterization).

B.6 Pattern AB.1 / AB.2 / AB.4

• Pattern AB.1: every PMID and NCT verified at draft step.
• Pattern AB.2: PMID 37385280 / 37385275 / 37385278 / 37385279 Lancet 2023 Aug incretin cluster inversion-prevention applied at every citation; TRIUMPH-1 NCT05929066 (NOT NCT05608252) applied at every citation; Loomba 2024 PMID 38856224 tirzepatide SYNERGY-NASH vs Sanyal 2024 PMID 38847460 survodutide same-NEJM-day inversion-prevention applied.
• Pattern AB.4: cascade scan applied — Coskun 2022 Cell Metab (NOT J Clin Invest) at every citation; Giblin 2026 design paper (NOT primary results) at every citation; Sanyal 2024 PMID 38858523 Phase 2a substudy (NOT Phase 3) at every citation; Parker 2025 PMID 40329607 pooled regulatory data (NOT SR) at every citation; Lakhani 2025 PMID 40383360 observational pharmacovigilance (NOT SR/MA) at every citation.

B.7 Cross-canonical consistency (module-level audit reference)

Cross-canonical consistency framework applies at module-level audit per /Internal/Module-5-Pipeline/README.md. This protocol’s calibration is consistent with the Retatrutide canonical v1.0-final (cross-referenced at every citation). Module-level audit will run when all 9 Module 5 protocols complete.

---

Appendix C. Self-audit findings

C.1 Pattern AA scan — “approved” / “FDA-approved” body-text usage

The protocol body text uses “FDA-approved” only in the following contexts (Pattern AA-compliant):

1. In the negative for retatrutide. “Retatrutide is NOT FDA-approved as of 2026-05-13” (and equivalent constructions). Body-text appears in §1.1, §1.2, §3.7, §6.6, §6.9, §8.7, §10.1, §10.2, §10.3, §10.5, §10.6, §10.7, §11.2, §12.1, §12.4, Appendix B.5.
2. For FDA-approved class comparators (semaglutide, tirzepatide, dulaglutide, resmetirom). Body-text appears in §1.2, §3.7, §4.3, §5.4, §6.6, §7.4, §7.5, §9.2, §10.5, §12.3.
3. For class-level FDA boxed warning framing (MTC / MEN-2 contraindication). Body-text appears in §2.4.
4. For anticipated retatrutide FDA approval scenarios (with explicit “anticipated” / “post-approval” / “if approved” qualification). Body-text appears in §1.1, §1.2, §4.3, §4.6, §5.2, §6.5, §8.3, §8.6, §10.2, §10.5.

No retatrutide regulatory claim in the body text uses “approved” / “FDA-approved” without explicit qualification. Self-audit CLEAN.

C.2 §10 framing-discipline diff against canonical anchors

§10.3 retatrutide-specific compounded framing diff against canonical Anchor 1 (semaglutide §8.3.2): retatrutide-specific reframing operates per canonical §8.3.2 Methodology Adaptation Memo Q5 Option B — leads with what compounded retatrutide IS in the pre-FDA-approval landscape; operational differences from the post-FDA-approval 503A/503B framework presented as factual scope, not deficit framing; closes with shared-decision-making at the sourcing-vendor-quality layer. Calibration consistent with canonical Anchor 1 retatrutide-specific calibration. Self-audit CLEAN.

§10.4 pregnancy framing diff against canonical Anchor 3 (semaglutide §6.8): pregnancy section LEADS with Parker 2025 PMID 40329607 human research-state data (“Incidence of congenital abnormalities appears relatively low”). PK arithmetic, animal-data + class-level Category-X-equivalent contraindication framing, and post-discontinuation weight-regain trajectory appear AFTER the research-state lead. Patient’s decision is patient-anchored. Calibration consistent with canonical Anchor 3. Self-audit CLEAN.

§10.5 comparator framing diff against canonical Anchor 4 (semaglutide §12.10 Pattern 6): 9-dimension fact presentation (weight magnitude, regulatory status, CV outcomes, MASH approval, kidney outcomes, NAION class-differentiation, mechanism-class differentiation, GI tolerability, route, cost). Opens with affirmation of all compounds; acknowledges tirzepatide weight-magnitude advantage explicitly (SURMOUNT-5 head-to-head); closes with shared-decision-making invitation. Pattern AA in-readout-vs-completed Phase 3 caveat verbatim. Calibration consistent with canonical Anchor 4 + retatrutide-specific Pattern AA addition. Self-audit CLEAN.

§10.6 off-label / extrapolation framing diff against canonical Anchor 5 (semaglutide §12.10 Pattern 8): off-label-dominant framing per retatrutide pre-approval state. Trial-population scope as fact; extrapolation as research-state-incompleteness; explicit off-label labeling; informed-consent acknowledgement; closes with shared-decision-making invitation. Calibration consistent with canonical Anchor 5 retatrutide-specific dominant calibration. Self-audit CLEAN.

C.3 §11 PMID / NCT against Retatrutide canonical verified footer

Every PMID and NCT in §11.4 / §11.5 / §11.6 / §11.7 verified against Retatrutide canonical v1.0-final §11 Primary-source citation appendix (which was itself verified at canonical Phase 10.5 PSV iter 1 CLEAN). Cascade-failure prevention: TRIUMPH-1 = NCT05929066 (NOT NCT05608252) consistently. Lancet 2023 Aug incretin cluster discipline applied. Coskun 2022 Cell Metab discipline applied. Giblin 2026 design paper discipline applied. Loomba 2024 / Sanyal 2024 same-NEJM-day discipline applied. Parker 2025 / Lakhani 2025 pub-type-precise framing applied. Self-audit CLEAN.

C.4 §1 Purpose pre-approval clinical-education framing

§1.1 opens with: “This protocol prepares clinicians for retatrutide’s anticipated availability based on Phase 3 readout data and provides a clinical-education framework… Current prescribing reality (2026-05-13). Retatrutide is in Phase 3 with the TRIUMPH program in active execution… Anticipated regulatory trajectory based on current sponsor disclosures and Phase 3 readout schedule: anticipated FDA submission Q4 2026, anticipated approval H1 2027 — conditional on Phase 3 results and on FDA review timelines… What this protocol IS NOT. It is not a current-prescribing protocol for a population at large. Current prescribing of retatrutide is restricted to (a) enrollment in an active TRIUMPH or TRANSCEND-T2D or SYNERGY-Outcomes Phase 3 trial under the trial protocol’s investigational-supply provision; (b) off-label clinical use of investigational supply where research-protocol acquisition pathways exist…”

The §1 Purpose carries the pre-approval clinical-education framing explicitly per the task-brief Pattern AA requirement. Self-audit CLEAN.

C.5 Items for Dr. Gross verification

The following items are flagged for Dr. Gross verification at the Step 4 gate:

1. Anticipated FDA approval timing claim (“anticipated FDA submission Q4 2026, anticipated approval H1 2027 conditional on Phase 3 results and FDA review timelines”) — verify against current Eli Lilly SEC filings and press releases. Pattern P pre-publication verification discipline applies. If specific submission timing has been Lilly-disclosed in a recent (post-2026-05-12) communication, update the protocol accordingly; if not disclosed, the anticipated H1 2027 framing is the maximum specificity per the canonical’s Pattern AA-precise discipline.

2. Anticipated post-approval titration schedule (§4.3 and §4.6 — 2 mg → 4 mg → 8 mg → 12 mg with 4-week intervals per the TRIUMPH Phase 3 design framework) — verify against the eventual FDA label at approval. The current protocol framing is anticipated framework based on Giblin 2026 design paper (PMID 41090431); label-specific schedule emerges from the FDA label.

3. Anticipated post-approval maintenance dose framework (§5.2 — 8 mg and 12 mg dose options) — verify against the eventual FDA label.

4. Anticipated taper schedule (§8.3 — 12 mg → 8 mg → 4 mg → 2 mg → off over ~12 weeks) — verify against the eventual FDA label and against the broader GLP-1 RA class taper framework.

5. TRIUMPH program enrollment status updates (§1.2, §1.5, §12.3) — verify against current ClinicalTrials.gov v2 API status at the time of clinical use. RECRUITING / ACTIVE_NOT_RECRUITING / COMPLETED status as of 2026-05-13 may have changed by the time of clinical-education delivery; the canonical’s Pattern AB.4 cascade discipline applies.

6. Voice Profile calibration — review §10.2 / §10.3 / §10.4 / §10.5 / §10.6 / §10.7 counseling-beat language against /Methodology/Voice Profile - Dr. Jeff Gross MD.md for tone, framing, and voice. Adjust as needed.

7. Pre-FDA-approval-compounded retatrutide framing (§10.3) — verify the Methodology Adaptation Memo Q5 Option B framing language is consistent with Dr. Gross’s clinical experience and judgment regarding patient-discourse triage for compounded retatrutide sourcing questions in the pre-FDA-approval state.

8. GCGR-component hepatic-biology surveillance framework (§5.3, §6.10, §6.12) — verify the ALT/AST monitoring posture and the transaminase-elevation-context framing against current hepatology consultation patterns. Phase 3 surveillance data may refine the specific monitoring intervals; the current framing is research-state-anchored to the Phase 2a MASLD substudy + GCGR mechanism research direction.

9. Cardiac glucagon-receptor research-state context (§5.3, §6.6) — verify the cardiac safety surveillance posture given the PMID 40613938 preclinical inotropic-effects finding. The TRIUMPH-3 + TRIUMPH-Outcomes Phase 3 cardiac safety primary endpoints will populate the human-trial-population cardiac safety evidence base; the current framing is research-state-anchored.

10. Pattern AA precision on anticipated post-approval label claims — verify that no anticipated indication claim implies pre-approval certainty. Every “anticipated” framing is explicit; every “if approved” / “post-approval” framing is explicit.

C.6 Production audit summary

• File path: /Users/dariapechaiko/Documents/VirtuDigital/Projects/Pepteon Academy/Synergy-Health-Academy/obsidian-peptides/Protocols/Retatrutide Protocol.md
• Word count target: 20,000-25,000 words.
• Production discipline: 6 strict incremental commits per the production-discipline standard.
• Pattern Z 5-anchor verbatim-anchor compliance: verified per §C.2.
• Pattern AA pre-approval-state precision: verified per §C.1 + §C.4.
• Pattern AB.4 identifier-integrity: verified per §C.3.
• §1 Purpose pre-approval clinical-education framing: verified per §C.4.
• Cross-canonical consistency: verified against Retatrutide canonical v1.0-final.

---

End of Retatrutide Clinical Protocol v1.0-draft.